<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006006" GROUP_ID="LIVER" ID="810504112212231632" MERGED_FROM="" MODIFIED="2011-09-07 23:34:45 +0200" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2011-09-07 23:34:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Prostaglandins for adult liver transplanted patients</TITLE>
<CONTACT MODIFIED="2011-09-07 23:34:45 +0200" MODIFIED_BY="Dimitrinka Nikolova"><PERSON ID="906FCD5782E26AA2010A531437192D4C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alexandre</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Cavalcanti</LAST_NAME><POSITION>Medical Coordinator of Clinical Research</POSITION><EMAIL_1>alexandrebiasi@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Education and Research Institute</DEPARTMENT><ORGANISATION>Hospital do Coração</ORGANISATION><ADDRESS_1>Rua Abílio Soares, 250</ADDRESS_1><ADDRESS_2>12 Andar</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04005-909</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>55 11 98829343</PHONE_1><PHONE_2>55 11 30536611</PHONE_2><FAX_1>+55 11 38864695</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-09-07 23:34:45 +0200" MODIFIED_BY="Dimitrinka Nikolova"><PERSON ID="906FCD5782E26AA2010A531437192D4C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alexandre</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Cavalcanti</LAST_NAME><POSITION>Medical Coordinator of Clinical Research</POSITION><EMAIL_1>alexandrebiasi@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Education and Research Institute</DEPARTMENT><ORGANISATION>Hospital do Coração</ORGANISATION><ADDRESS_1>Rua Abílio Soares, 250</ADDRESS_1><ADDRESS_2>12 Andar</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04005-909</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>55 11 98829343</PHONE_1><PHONE_2>55 11 30536611</PHONE_2><FAX_1>+55 11 38864695</FAX_1></ADDRESS></PERSON><PERSON ID="A43F5E6982E26AA201B7A53152AB0413" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Camila Paiva</FIRST_NAME><LAST_NAME>De Vasconcelos</LAST_NAME><EMAIL_1>camilavasc@hotmail.com</EMAIL_1><EMAIL_2>camilavasc@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Intensive Care Unit</DEPARTMENT><ORGANISATION>Hospital São Camilo</ORGANISATION><ADDRESS_1>Prado Valadares, 25 apto 72A</ADDRESS_1><ADDRESS_2>CEP 05365-060</ADDRESS_2><CITY>Sao Paulo</CITY><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 9900 7920</PHONE_1><PHONE_2>+55 11 3735 5025</PHONE_2><FAX_1>+55 11 3746 9411</FAX_1></ADDRESS></PERSON><PERSON ID="73502683520037060810091011055317" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mariana</FIRST_NAME><LAST_NAME>Perroni de Oliveira</LAST_NAME><EMAIL_1>mperroni@gmail.com</EMAIL_1><EMAIL_2>marianapo@einstein.br</EMAIL_2><ADDRESS><ORGANISATION>Adult Intensive Care Unit - 5th Floor</ORGANISATION><ADDRESS_1>Av. Albert Einstein, 627/701</ADDRESS_1><ADDRESS_2>CEP 05652-900</ADDRESS_2><CITY>Sao Paulo - SP</CITY><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="26E1BABF82E26AA2000C5DBB18A6AA7A" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Edna</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Rother</LAST_NAME><POSITION>Librarian</POSITION><EMAIL_1>erother@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Library</DEPARTMENT><ORGANISATION>Hospital Israelita Albert Einstein</ORGANISATION><ADDRESS_1>Rua Piassanguaba, 2087</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04060-003</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>55 11 50710685</PHONE_1><PHONE_2>55 11 99037419</PHONE_2></ADDRESS></PERSON><PERSON ID="A43F7E5E82E26AA201B7A53113EDBA92" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Leonardo</FIRST_NAME><MIDDLE_INITIALS>JR</MIDDLE_INITIALS><LAST_NAME>Ferraz</LAST_NAME><POSITION>Staff</POSITION><EMAIL_1>leoferraz@einstein.br</EMAIL_1><ADDRESS><DEPARTMENT>Intensive Care Unit</DEPARTMENT><ORGANISATION>Hospital Israelita Albert Einstein</ORGANISATION><ADDRESS_1>Rua Itapecurus, 282 apt 192b</ADDRESS_1><CITY>São Paulo</CITY><ZIP>06454-080</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>55 11 4195 3206</PHONE_1><PHONE_2>55 11 9965 5489</PHONE_2><FAX_1>+55 119965 5489</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-09-01 06:59:25 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="31" MONTH="8" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="4" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="9" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2009-10-10 16:27:29 -0300" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2010-02-15 08:55:03 -0200" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2010-04-08 08:31:35 -0300" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-02-15 11:00:20 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<SOURCE MODIFIED="2010-02-15 11:00:20 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<NAME>None. The authors did not receive any internal financial support for conducting this review</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-04-08 08:31:35 -0300" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-04-08 08:31:35 -0300" MODIFIED_BY="[Empty name]">
<NAME>None. The authors did not receive any external financial support for conducting this review</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-09-07 16:06:40 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2011-09-01 07:14:31 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2011-08-27 12:56:39 -0300" MODIFIED_BY="Dimitrinka Nikolova">Prostaglandins for liver transplanted patients</TITLE>
<SUMMARY_BODY MODIFIED="2011-09-01 07:14:31 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Liver transplantation is the most effective treatment for patients with advanced liver disease (cirrhosis). However, early postoperative problems such as graft failure or acute renal failure requiring dialysis are common. Patients evolving with such problems are at increased risk of death. Prostaglandins are substances produced by the human body with several actions including vasodilation. They might prevent perioperative hepatic and kidney lesions caused by lack of blood supply. This review summarised and meta-analysed the evidence from randomised clinical trials on the effect of prostaglandins for adult liver transplanted patients. We found ten trials randomising 652 patients. Evidence from these trials is inconclusive on the role of prostaglandins regarding outcomes such as death or liver re-transplantation. The risk of acute kidney failure requiring dialysis may be reduced by two thirds if a liver transplant patient receives prostaglandins, although the level of evidence is only moderate due to risks of systematic errors (bias) and random errors (play of chance). No severe adverse events are reported. Therefore, further randomised trials with low risk of bias and sufficient sample sizes are still needed to establish whether prostaglandins should be administered for liver transplanted patients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-09-07 16:04:44 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2011-08-27 12:56:39 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Prostaglandins may reduce ischaemic injury after liver transplantation. Several small randomised trials have evaluated the effects of prostaglandins in patients undergoing liver transplantation. Results of these trials are inconsistent, and none has enough power to reliably exclude effects of prostaglandins.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-02-16 08:17:45 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the benefits and harms of prostaglandin E1 or E2 in adult liver-transplanted patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-09-01 06:59:49 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I>, MEDLINE, EMBASE, Science Citation Index Expanded, and LILACS (search on 20 April 2011). In addition, we perused the reference lists of the identified studies and contacted trials investigators, and national and international experts in order to identify more trials for the review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-08-24 06:14:34 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included randomised clinical trials evaluating prostaglandin E1 or E2 initiated in the perioperative period versus placebo or standard treatment for adult patients undergoing liver transplantation. We did not apply any language or publication status restrictions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-09-01 08:34:00 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two authors independently evaluated methodological quality, ie, risk of bias of the included trials, and extracted data using standardised data extraction forms. We contacted trial investigators in attempt to retrieve information not available in the original manuscripts. We used random-effects model meta-analyses and fixed-effect model meta-analyses to estimate the odds ratio with 95% confidence interval (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-09-07 16:04:44 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included ten trials in which 652 patients were randomised. The risk of bias was considered high in most trials. There was no significant effect of prostaglandins on all-cause mortality (37/298[12.4%] in prostaglandin group versus 47/312[15.1%] in control group; OR 0.84, 95% CI 0.53 to 1.37; I<SUP>2 </SUP>= 0%), on primary non-function of the allograft (8/238 [3.4%] versus. 16/250[6.4%] ;OR 0.55, 95% CI 0.23 to 1.33; I<SUP>2 </SUP>= 0%), and on liver re-transplantation (12/161[7.5%] versus 14/171[8.2%]; OR 0.99, 95% CI 0.44 to 2.25; I<SUP>2 </SUP>= 0%). Prostaglandins seemed to significantly decrease the risk of acute kidney failure requiring dialysis (13/158[8.2%] versus 34/171[9.9%]; OR 0.37, 95% CI 0.18 to 0.75; I<SUP>2 </SUP>= 0%). There was no significant increase in the risk of adverse events with prostaglandins.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-08-27 12:56:39 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no evidence that the administration of prostaglandins to liver transplanted patients reduces the risk of death, primary non-function of the allograft, or liver re-transplantation. Prostaglandins might reduce the risk of acute kidney failure requiring dialysis, but the quality of the evidence is considered only moderate due to high risk of bias in most of the included trials. Moreover, there are risks of outcome measure reporting bias and random errors. Therefore, further randomised, placebo-controlled trials are deemed necessary.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-09-07 16:06:40 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Liver transplantation is recognised as the most effective treatment for patients with end-stage liver disease (<LINK REF="REF-Anonymous-1994" TYPE="REFERENCE">Anonymous 1994</LINK>). The number of transplants has increased in most countries. In the United States, for example, the number of liver transplants grew from 2676 in the year of 1990 to 4595 in 2000, and 6009 in 2010 (<LINK REF="REF-OPTN-2011" TYPE="REFERENCE">OPTN 2011</LINK>). Corresponding numbers in Europe were 2126 in 1990, 4929 in 2000, and 5765 in 2008 (<LINK REF="REF-ELTR-2011" TYPE="REFERENCE">ELTR 2011</LINK>). As a result of improvements in immunosuppression, organ conservation, intensive therapy medicine, and surgical technique, one-year survival is currently in the range of 75% to 95% (<LINK REF="REF-Klein-1999a" TYPE="REFERENCE">Klein 1999a</LINK>). Despite these overall satisfactory results, important problems for patients undergoing liver transplantation remain, including primary non-function of the allograft and acute kidney failure requiring dialysis. After orthotopic liver transplantation, some degree of clinical and biochemical dysfunction almost invariably occurs, the severity of which correlates with the degree of hepatic injury. The most severe presentation is known as primary non-function of the allograft. The primary non-function of the allograft condition affects 7% to 19% of liver transplantation recipients. It usually requires emergency re-transplantation (<LINK REF="REF-Desch_x00ea_nes-1998" TYPE="REFERENCE">Deschênes 1998</LINK>) and increases sharply the risk of death. For patients with this condition, the mortality is 80% to 100% if they do not undergo re-transplantation (<LINK REF="REF-Tancharoen-1992a" TYPE="REFERENCE">Tancharoen 1992a</LINK>).</P>
<P>A major reason for primary non-function of the allograft is ischaemic injury. The decrease in ratio of prostacyclin (PGI2) and thromboxane (TxA2) is present in ischaemia-reperfusion injury, promoting local adhesion of leukocytes and platelet aggregation. The administration of prostacyclin has been demonstrated to reduce ischaemic injury after liver transplantation and increase hepatic oxygen supply. Improved hepatic microcirculation is another postulated mechanism by which prostacyclin could improve liver function (<LINK REF="REF-Neumann-2000a" TYPE="REFERENCE">Neumann 2000a</LINK>).</P>
<P>Acute renal failure is another frequent and severe complication following liver transplantation. A reduction in the renal synthesis of vasodilator prostaglandins was proposed as having an important role in the pathogenesis of renal insufficiency associated with hepatic dysfunction. The administration of prostaglandins might help preventing the occurrence of acute renal failure (<LINK REF="REF-Greig-1989b" TYPE="REFERENCE">Greig 1989b</LINK>).</P>
<P>Adverse effects are uncommon after administration of prostaglandins. They are usually dose-related and rapidly reverted after discontinuation. The most common adverse effects are hypotension, diarrhoea, flushing, and headache. Prostaglandins also inhibit platelet aggregation; however, there is no evidence of increased bleeding risk.</P>
<P>Several small randomised trials involving treatment with prostaglandins were undertaken to examine the effects of these drugs on patients undergoing liver transplantation (<LINK REF="REF-Henley-1995a" TYPE="REFERENCE">Henley 1995a</LINK>; <LINK REF="REF-Klein-1996a" TYPE="REFERENCE">Klein 1996a</LINK>; <LINK REF="STD-Manasia-1996" TYPE="STUDY">Manasia 1996</LINK>). However, none was sufficiently powered to determine the effects of prostaglandins on mortality. Moreover, the results observed for other outcomes, such as primary nonfunction of the allograft or acute kidney failure, were inconsistent. We could not find any systematic reviews or meta-analyses on prostaglandins for liver-transplanted patients. Therefore, we aimed to determine if the perioperative administration of prostaglandins would reduce overall mortality, primary non-function of the allograft, and acute renal failure in liver transplanted patients.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-07-24 22:28:22 -0300" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial and harmful effects of prostaglandin E1 or E2 in adult liver-transplanted patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-09-05 10:21:08 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2011-09-01 07:35:31 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2011-07-13 06:40:15 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included only randomised clinical trials. Quasi-randomised trials were not included. We considered for inclusion randomised clinical trials regardless of their publication status, language, blinding, size, duration of patient follow-up, or their primary objectives and reported outcomes.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Liver transplant recipients, aged 18 years old or more.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-08-27 12:56:39 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Experimental treatment: prostaglandin E1 or E2, initiated in the perioperative period. We defined the perioperative period as the period between the beginning of liver surgery and up to 48 hours after transplantation.</LI>
<LI>Control treatment: no intervention (ie, the same standard treatment as the one given to the experimental intervention group except the use of prostaglandins) or placebo.</LI>
</UL>
<P>Co-interventions were allowed if received equally by all intervention groups of the trial.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-09-01 07:35:31 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Primary outcome</B>
<BR/>
</P>
<UL>
<LI>All-cause mortality.</LI>
</UL>
<P>
<B>Secondary outcomes<BR/>
</B>
</P>
<UL>
<LI>Number of patients with primary non-function of the allograft.</LI>
<LI>Number of patients with liver re-transplantation.</LI>
<LI>Number of patients with acute renal failure requiring dialysis.</LI>
<LI>Length of hospital stay.</LI>
<LI>Adverse events; analyses of adverse events in total and specific reported adverse events (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).</LI>
</UL>
<P>The definitions of primary non-function of the allograft were those used in the original trials, except when a trial did not define or report this outcome. Whenever it happened, we asked the author of the trial to provide data according to the following definition proposed by the Organ Procurement and Transplantation Network (<LINK REF="REF-OPTN-2010" TYPE="REFERENCE">OPTN 2010</LINK>):</P>
<UL>
<LI>Serum aspartate aminotransferase (AST) &#8805; 3,000 IU/l within seven days of implantation and one or both of the following:</LI>
</UL>
<UL>
<UL>
<LI>An international normalised ratio &#8805; 2.5.</LI>
<LI>Acidosis, defined as having an arterial pH &#8804; 7.30 or venous pH &#8804; 7.25 and/or lactate &#8805; 4 mmol/l.</LI>
</UL>
</UL>
<P>The outcomes above were not considered as criteria for including trials in this review, ie, a randomised trial did not have to report all these outcomes in order to be included in the present review.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-08-27 12:56:39 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched The Cochrane Hepato-Biliary Group Controlled Trials Register<I> </I>(<LINK REF="REF-Gluud-2011" TYPE="REFERENCE">Gluud 2011</LINK>), The Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I>, MEDLINE (via PubMed), EMBASE, Science Citation Index Expanded, and LILACS (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>) until April 2011. The search strategies with the time span of the searches are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We identified further trials from the reference lists of identified studies. We did not apply any language or publication status restrictions.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-09-05 10:21:08 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Assessment of study eligibility</B>
<BR/>All references identified through our searches were independently evaluated by two authors (ABC and CPV, ABC and LJRF, or CPV and LJRF). If at least one of the authors considered that the abstract of a reference might possibly include a randomised clinical trial of interest to the review, the full text was obtained for complete assessment. Two authors independently assessed the eligibility of the trial (ABC and CPV, ABC and LJRF, or CPV and LJRF). In case of disagreements, the authors discussed the reasons for their decisions. If a disagreement was not solved during the process, a third author settled it (ABC, CPV, or LJRF). In case of any doubts about the trial design (for example, observational study compared to randomised clinical trial), the author of the publication was contacted.</P>
<P>The selected trials were checked for multiplicity of publication. We identified groups of publications that were possibly multiple. We confirmed multiplicity and obtained data by contacting authors of the publication. We listed publications originating from the same trial and extracted data from the publications to get the most complete and valid set of data.</P>
<P>
<B>Assessment of risk of bias</B>
<BR/>We used criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and The Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2011" TYPE="REFERENCE">Gluud 2011</LINK>) to assess the risk of bias in included trials. Teams of two authors independently evaluated risk of bias of the trials, following exactly the same procedures as for eligibility evaluation. We used the following risk of bias domains (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>).</P>
<P>
<I>Allocation sequence generation</I> <BR/>- Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are adequate if performed by an independent adjudicator.<BR/>- Uncertain risk of bias: the trial is described as randomised, but the method of sequence generation was not specified.<BR/>- High risk of bias: the sequence generation method is not, or may not be, random. Quasi-randomised studies, those using dates, names, or admittance numbers in order to allocate patients are inadequate and were excluded for the assessment of benefits but not for harms.<BR/>
<BR/>
<I>Allocation concealment</I>
<BR/>- Low risk of bias: allocation was controlled by a central and independent randomisation unit, sequentially numbered, opaque and sealed envelopes or similar, so that intervention allocations could not have been foreseen in advance of, or during, enrolment.<BR/>- Uncertain risk of bias: the trial was described as randomised, but the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.<BR/>- High risk of bias: if the allocation sequence was known to the investigators who assigned participants, or if the study was quasi-randomised. Quasi-randomised studies were excluded for the assessment of benefits but not for harms.<BR/>
<BR/>
<I>Blinding</I>
<BR/>- Low risk of bias: the trial was described as blinded, the parties that were blinded, and the method of blinding was described so that knowledge of allocation was adequately prevented during the trial.<BR/>- Uncertain risk of bias: the trial was described as blinded, but the method of blinding was not described so that knowledge of allocation was possible during the trial.<BR/>- High risk of bias, the trial was not blinded so that the allocation was known during the trial.</P>
<P>
<I>Incomplete outcome data</I>
<BR/>- Low risk of bias: the numbers and reasons for dropouts and withdrawals in all intervention groups were described, or if it was specified that there were no dropouts or withdrawals.<BR/>- Uncertain risk of bias: the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.<BR/>- High risk of bias: the number or reasons for dropouts and withdrawals were not described.</P>
<P>
<I>Selective outcome reporting</I>
<BR/>- Low risk of bias: pre-defined, or clinically relevant and reasonably expected outcomes are reported on.<BR/>- Uncertain risk of bias: not all pre-defined or clinically relevant and reasonably expected outcomes are reported on, or are not reported fully, or it is unclear whether data on these outcomes were recorded or not.<BR/>- High risk of bias: one or more clinically relevant and reasonably expected outcomes were not reported on; data on these outcomes were likely to have been recorded.</P>
<P>
<I>Other potential threats to validity</I>
</P>
<P>- Low risk of bias: the study appears free of other sources for bias.<BR/>- Uncertain risk of bias: there may be a risk of bias, but there is either insufficient information to assess whether an important risk of bias exists or insufficient rationale or evidence that an identified problem will introduce bias.<BR/>- High risk of bias: there was extreme baseline imbalance, if it was stopped early for benefit or unclear reasons, or the trial has been claimed to be fraudulent or had some other problems.</P>
<P>We considered that a trial was at low risk of bias when it was of low risk of bias in respect to all domains evaluated (allocation sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential threats to validity). In all other instances, the trial was considered a trial of high risk of bias.</P>
<P>
<B>Data collection</B>
<BR/>A data extraction form was designed to include information about the trials (quality and setting), demographic characteristics of patients studied, characteristics of interventions (dose and duration), and relevant outcomes. When data on relevant events were not reported, we contacted authors to obtain it.</P>
<P>Teams of two authors independently extracted data from all randomised clinical trials that fulfilled eligibility criteria, following exactly the same process as for eligibility evaluation.</P>
<P>
<B>Statistical analyses</B>
<BR/>Data from all included randomised trials were meta-analysed to estimate the pooled odds ratio (OR) with 95% confidence interval (CI) using both fixed-effect (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>) and random-effects models (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). We reported only the results of the random-effects model when both models reached the same conclusion regarding significant or not significant intervention effect. However, in case the two models reached contrasting results, we reported both models.</P>
<P>The analyses were based on intention-to-treat data from the individual trials whenever possible. Patients who were withdrawn from treatment were also analysed according to the group he or she was allocated to as long as they were followed-up. Every effort was done to obtain complete information about patients' outcomes, including contacting trial authors. However, we did not include in the denominator patients with no follow-up. We anticipated this would be quite a rare situation in the setting of liver transplantation.</P>
<P>We evaluated the beneficial or harmful effects of administration of a perioperative prostaglandin E1 or E2 in subgroups regarding:<BR/>
</P>
<UL>
<LI>Living donor transplant compared to cadaver liver transplant.</LI>
<LI>Different doses of prostaglandins.</LI>
<LI>Different duration of administration of prostaglandins.</LI>
</UL>
<P>The presence of heterogeneity across trials was evaluated using I<SUP>2</SUP> statistics (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>) and standard chi-squared tests for homogeneity for each outcome analysis. A I<SUP>2</SUP> value represents the percentage of total variation across trials that is due to heterogeneity rather than chance. We considered an I<SUP>2</SUP> value less than 25% as low, and a I<SUP>2</SUP> value more than 75% as high. We looked for potential publication bias and other biases associated with small study effects by constructing funnel plots (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). Funnel plots are simple scatter plots of the treatment effects obtained from individual studies on the vertical axis (for example, log OR) against some measure of study size on the horizontal axis (for example, standard error of log OR).</P>
<P>We had originally planned to carry out univariate and multivariate random-effects meta-regression models to analyse potential clinical and study quality factors that might influence treatment effects, that is, in an attempt to explain heterogeneity (<LINK REF="REF-Thompson-1999" TYPE="REFERENCE">Thompson 1999</LINK>; <LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>). The following variables would have been considered: standard error of log odds ratio, publishing status (MEDLINE indexed or not), bias risk (allocation sequence generation, allocation sequence concealment, blinding, incomplete outcome data, early stopping, selective outcome reporting bias, and other threats to validity), living versus cadaver donor transplantation, different dose of prostaglandins, different time of administration. However, as we have not found substantial heterogeneity for any outcome and we only identified few trials, meta-regression was not carried out.</P>
<P>All P-values reported were two-tailed, and values lower than 0.05 were considered significant, except for the chi-squared test for homogeneity. This method has low sensitivity for detecting heterogeneity using few trials; therefore, we considered a P-value lower than 0.10 as statistically significant. The statistical analysis was performed with Review Mananger 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-09-07 16:06:40 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2011-09-07 16:06:40 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We initially identified 305 potentially relevant studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After evaluating their abstracts (or titles), 265 studies were excluded because they were not randomised or did not compare a prostaglandin versus no intervention or placebo. The full-texts of the remaining 40 studies were analysed, with 27 being considered non-eligible. This left 13 appropriate reports of randomised trials to be included in the review. Three of them were duplicate reports (<LINK REF="REF-Himmelreich-1993a" TYPE="REFERENCE">Himmelreich 1993a</LINK>; <LINK REF="REF-Chavin-1996" TYPE="REFERENCE">Chavin 1996</LINK>; <LINK REF="REF-Neumann-1999" TYPE="REFERENCE">Neumann 1999</LINK>) which left us with 10 randomised trials eligible for this systematic review (<LINK REF="STD-Alevizacos-1993" TYPE="STUDY">Alevizacos 1993</LINK>; <LINK REF="STD-Himmelreich-1993" TYPE="STUDY">Himmelreich 1993</LINK>; <LINK REF="STD-Henley-1995" TYPE="STUDY">Henley 1995</LINK>; <LINK REF="STD-Ismail-1995" TYPE="STUDY">Ismail 1995</LINK>; <LINK REF="STD-Klein-1996" TYPE="STUDY">Klein 1996</LINK>; <LINK REF="STD-Manasia-1996" TYPE="STUDY">Manasia 1996</LINK>; <LINK REF="STD-Neumann-1998" TYPE="STUDY">Neumann 1998</LINK>; <LINK REF="STD-Neumann-2000" TYPE="STUDY">Neumann 2000</LINK>; <LINK REF="STD-Hidalgo-2002" TYPE="STUDY">Hidalgo 2002</LINK>; <LINK REF="STD-B_x00e4_rthel-2008" TYPE="STUDY">Bärthel 2008</LINK>). The trial by Neuman et al, published in 1998, did not report the number of patients randomised to the treatment and the control group, only the total number of patients enrolled (<LINK REF="STD-Neumann-1998" TYPE="STUDY">Neumann 1998</LINK>). Therefore, it was not possible to use data from this trial in any of the meta-analyses.</P>
<P>All trials were published between 1993 and 2008 and enrolled a total of 652 adult liver transplant recipients, all receiving cadaver grafts (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The median sample size was 51 patients, ranging from 20 to 160.</P>
<P>Seven trials evaluated intravenous prostaglandin E1, one trial used oral/enteral enisoprost (a prostaglandin E1) analogue, one trial used iloprost, and one trial used prostacyclin. The intervention was started right before or during surgery in most trials, or within the first 24 hours postoperatively in two trials (<LINK REF="STD-Ismail-1995" TYPE="STUDY">Ismail 1995</LINK>; <LINK REF="STD-Manasia-1996" TYPE="STUDY">Manasia 1996</LINK>).</P>
<P>One of the included trials was published only at a medical meeting (<LINK REF="STD-B_x00e4_rthel-2008" TYPE="STUDY">Bärthel 2008</LINK>), and another trial only as a doctoral thesis (<LINK REF="STD-Hidalgo-2002" TYPE="STUDY">Hidalgo 2002</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-09-05 10:21:25 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>In general, the included randomised trials had high risk of bias (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Five trials had adequate sequence generation while in the remaining five trials this domain was unclear. Allocation concealment was adequate in four trials and unclear in six. Blinding of participants, health care personnel, and outcome assessors was adequate in three out of ten trials, inadequate in three, and unclear in four. Outcome data were incomplete in three trials and it was unclear in one trial. Two trials were free of suggestion of selective outcome reporting, while for the remaining eight, it was unclear whether selective outcome reporting might have happened. Other threats to validity, such as stopping early for benefit or unclear reason, and important baseline imbalances were absent in three trials, unclear in six, and present in one trial.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-09-01 08:16:16 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Nine randomised trials had data available on the primary outcome, all-cause mortality. These trials included 622 patients, but data for only 610 are available, because 11 patients were excluded from analyses in the trial by Hidalgo et al (<LINK REF="STD-Hidalgo-2002" TYPE="STUDY">Hidalgo 2002</LINK>) and one patient in the trial by Henley et al (<LINK REF="STD-Henley-1995" TYPE="STUDY">Henley 1995</LINK>). No deaths occurred in three randomised trials (<LINK REF="STD-Himmelreich-1993" TYPE="STUDY">Himmelreich 1993</LINK>; <LINK REF="STD-Manasia-1996" TYPE="STUDY">Manasia 1996</LINK>; <LINK REF="STD-Neumann-2000" TYPE="STUDY">Neumann 2000</LINK>). Thus, only the remaining six trials contributed data on all-cause mortality. Prostaglandin administration had no significant effect on all-cause mortality (OR 0.84, 95% CI 0.52 to 1.37; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>There was no significant evidence of the effect of prostaglandins on the risk of primary non-function of the allograft (OR 0.55, 95% CI 0.23 to 1.33; I<SUP>2 </SUP>= 0%; 6 trials with 488 patients) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). However, there were only 24 events from four trials contributing to this analysis which resulted in a wide confidence interval.</P>
<P>There was no significant effect of prostaglandins on the incidence of liver re-transplantation (OR 0.99, 95% CI 0.44 to 2.25; I<SUP>2 </SUP>= 0%; 5 trials with 332 patients) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). This analysis was also based on few events, which led to an imprecise estimate of effect.</P>
<P>A significant beneficial effect of prostaglandins on the risk of acute kidney failure requiring dialysis was observed (OR 0.37, 95% CI 0.18 to 0.75; I<SUP>2 </SUP>= 0%; 4 trials with 329 patients) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>There was no significant effect of prostaglandins on length of hospital stay (mean difference -4.8 days; 95% CI -22.7 to 13.1; I<SUP>2 </SUP>= 90%; 2 trials with 190 patients) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>Only three patients with hypotension were reported in one randomised trial, all in the placebo group (Fisher's exact test P value = 0.25). No other significant adverse events were reported in the included trials.</P>
<P>Since no evidence of effect on the main outcome mortality was observed in the pooled results and only six trials contributed data to this analysis, we did not attempt sub-group analyses according to bias risk, different doses, or length of administration of prostaglandins. No randomised trials evaluated recipients of living donor liver grafts.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-09-05 10:21:53 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY_OF_RESULTS MODIFIED="2011-09-05 10:21:53 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>There was no evidence of significant effect of prostaglandins on all-cause mortality. However, the 95% CI were wide, with values compatible with either a clinically relevant harmful or beneficial effect. Therefore, it is possible that further trials might change this conclusion.</P>
<P>There was also no evidence of effects on the secondary outcomes such as primary non-function of the allograft, liver re-transplantation, length of hospital stay, and hypotension. The available evidence suggests a reduction in the risk of acute kidney failure requiring dialysis. However, the risks of bias was considered high in all trials, and our review suffers from outcome measure reporting bias as well as risk of random errors.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-07-25 19:34:17 -0300" MODIFIED_BY="[Empty name]">
<P>The results of this systematic review are applicable to most recipients of liver transplants, although it is relevant to mention that we found no trials including recipients of living donor grafts.</P>
<P>We were able to find trials on all pre-specified outcomes, but data were available from few trials. For instance, nine trials provided data on mortality, but only six trials had at least one event, thus contributing to analysis. This scenario was worse for all the secondary outcomes: only four trials contributed to primary non-function of the allograft, four trials to re-transplantation, four trials to renal failure, one trial to length-of-stay in hospital, and one to hypotension. This raises the risk that there may be selective outcome reporting bias, in particular because those outcomes are easy to assess (<LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-09-01 08:17:59 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Risk of bias across the trials was high. Most trials had limitations in the randomisation process, blinding of participants and investigators, incomplete outcome data, and unclear or inadequate stopping early for benefit, which may have introduced bias in the estimates of effect. Four trials did not provide baseline data according to treatment groups impeding us to assess whether important imbalances were present. The remaining six trials had well balanced baseline characteristics. Selective outcome reporting bias is also an issue as noted above.</P>
<P>Besides limitations due to elevated risk of bias, the effect estimates for all outcomes were limited by serious imprecision due to few events. Therefore, although a statistically significant effect was not observed except for acute kidney failure needing dialysis, estimates of effect of prostaglandins on important outcomes (mortality, primary non-function, liver re-transplantation) are compatible with both relevant benefit or harm. Therefore, the GRADE level of evidence was considered low for these outcomes.</P>
<P>Acute kidney failure requiring dialysis was the only outcome prostaglandins seemed to prevent. However, this evidence is limited by risk of bias due to selective outcome reporting and the possibility of a false-positive result due to multiple hypothesis testing. Recently, Pereira et al has empirically shown that initial estimates from meta-analysis with small number of events (less than 300 events) are, on average, inflated by about 50% (<LINK REF="REF-Pereira-2011" TYPE="REFERENCE">Pereira 2011</LINK>). Therefore, we judged the quality of evidence as moderate according to the GRADE system (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>), which means that this observation needs confirmation in future trials.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>In order to ensure a high degree of internal and external validity, we followed a systematic approach for trial identification, trial selection, data abstraction, and analysis. We searched for all relevant trials using sensitive and validated search strategies in several bibliographic databases. Trials were included regardless of publication status or language. Two trials not published in scientific periodicals (<LINK REF="STD-Hidalgo-2002" TYPE="STUDY">Hidalgo 2002</LINK>; <LINK REF="STD-B_x00e4_rthel-2008" TYPE="STUDY">Bärthel 2008</LINK>) were identified and included in this review, providing evidence of our efforts to minimise the risk of publication bias. Original investigators were contacted, although only one, Dr. Manasia, was able to contribute with additional information. The failure to obtain further information from the other investigators impaired the analysis of most outcomes.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-07-25 19:34:49 -0300" MODIFIED_BY="[Empty name]">
<P>We were unable to find any other meta-analysis or systematic review on the topic.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-09-05 10:22:53 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>This review summarises the best available evidence so far on the effects of prostaglandin administration for patients undergoing liver transplantation. The overall quality of evidence across all comparisons is very low to moderate using the GRADE system (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>). The intervention showed no effect on all-cause mortality (the primary outcome) or primary non-function of the allograft, liver-retransplantation, length of hospital stay, or hypotension.</P>
<P>The results of the randomised trials suggest a reduction on acute kidney failure requiring dialysis. However, this observation is limited by the risk of selective outcome reporting bias and the possibility of a false-positive result due to multiple hypothesis testing. Thus, more data are clearly needed on the effect of prostaglandins on kidney function.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-09-05 10:22:53 -0300" MODIFIED_BY="[Empty name]">
<P>There is still a need for adequately powered trials with low risk of bias to assess the effects of prostaglandins for patients undergoing liver transplantation.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-09-01 08:47:25 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Dr. Anthony Manasia for contributing with additional unpublished data (<LINK REF="STD-Manasia-1996" TYPE="STUDY">Manasia 1996</LINK>) to this review.</P>
<P>Dimitrinka Nikolova and Sarah Louise Klingenberg for assistance during all the systematic review steps. Christian Gluud and Ronald Koretz for valuable insights.</P>
<P>Protocol<BR/>Peer Reviewers: Ali Canbay, Germany; Jesper Brok, Denmark; Lise Lotte Gluud, Denmark.<BR/>Contact Editor: Christian Gluud, Denmark.</P>
<P>Review<BR/>Peer Reviewers: Nadine Shehata, Canada; Dr. Georgios C. Sotiropoulos, Germany.<BR/>Contact Editor: Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-09-01 08:22:05 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Alexandre Biasi Cavalcanti: originated the idea, prepared the protocol, developed and executed the search strategy, selected relevant studies, extracted data from studies, performed statistical analyses, prepared the manuscript, and co-ordinated the review process.<BR/>Mariana Perroni de Oliveira: prepared the review.<BR/>Camila Paiva de Vasconcelos: originated the idea, prepared the protocol, executed the search strategy, selected and obtained relevant studies, extracted data from studies, and prepared the manuscript.<BR/>Leonardo José Rolim Ferraz: originated the idea, prepared the protocol, selected relevant studies, extracted data from studies, and prepared the review.<BR/>Edna Terezinha Rother: prepared the protocol, developed and executed the search strategy.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-09-01 08:23:02 -0300" MODIFIED_BY="[Empty name]">
<P>Assessement of risk of bias in included studies was slightly modified in order to follow the recommendations from the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1 (updated in March 2011) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Therefore, 'incomplete outcome data' domain substituted the 'follow-up', and selective outcome reporting was added.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2011-07-20 07:27:43 -0300" MODIFIED_BY="Dimitrinka Nikolova"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-09-05 09:24:13 -0300" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-09-05 09:18:08 -0300" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-09-05 09:09:45 -0300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alevizacos-1993" MODIFIED="2010-04-08 07:40:08 -0300" MODIFIED_BY="[Empty name]" NAME="Alevizacos 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-04-08 07:40:08 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alevizacos P, Bechstein WO, Rossaint R, Neuhaus P</AU>
<TI>Faillure of PGE1 to prevent allograft reperfusion injury in a prospective randomized trial</TI>
<SO>Transplantation Proceedings</SO>
<YR>1993</YR>
<VL>25</VL>
<PG>2545-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00e4_rthel-2008" MODIFIED="2011-08-26 07:22:26 -0300" MODIFIED_BY="[Empty name]" NAME="Bärthel 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 07:40:16 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bärthel E, Rauchfus F, Habrecht O, Koch A, Klinzing S, Marxs G, et al</AU>
<TI>Impact of iloprost on early graft viability after liver transplantation - Results of a prospective randomized controlled clinical trial</TI>
<SO>Liver Transplantation</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>S1</NO>
<PG>S137</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-26 07:22:26 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bärthel E</AU>
<TI>ISRCTN 95672167 - Impact of iloprost on early graft viability after liver transplantation</TI>
<SO>www.controlled-trials.com/ISRCTN95672167/95672167</SO>
<YR>9 October 2008 (accessed 26 August 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henley-1995" MODIFIED="2009-03-06 15:59:44 -0300" MODIFIED_BY="[Empty name]" NAME="Henley 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-03-06 15:59:44 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henley KS, Lucey MR, Normolle DP, Merion RM, McLaren ID, Crider BA, et al</AU>
<TI>A double-blind, randomized, placebo controlled trial of prostaglandin E1 in liver transplantation</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>366-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hidalgo-2002" MODIFIED="2011-09-05 09:09:45 -0300" MODIFIED_BY="[Empty name]" NAME="Hidalgo 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-09-05 09:09:45 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hidalgo EL, Margaritt CC</AU>
<TI>Hemodynamic study of liver transplantation: Ischemia-reperfusion injury analysis and evaluation of intra-portal prostaglandin E1 administration in the reperfusion phase</TI>
<TO>Estudio hemodinámico del transplante hepático: Análisis de la lésion de isquemia-reperfusión y valoración de la administración intraportal de prostaglandina E1 en la fase de revascularización</TO>
<SO>Doctoral Thesis</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Himmelreich-1993" MODIFIED="2011-08-26 07:31:37 -0300" MODIFIED_BY="[Empty name]" NAME="Himmelreich 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-08-26 07:23:20 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Himmelreich G, Hundt K, Bechstein WO, Rossaint R, Neuhaus P, Riess H</AU>
<TI>Influence of prostaglandin E1 infusion on hemostasis in orthotopic liver transplantation</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>1993</YR>
<VL>19</VL>
<NO>3</NO>
<PG>273-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-26 07:31:37 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Himmelreich G, Hundt K, Neuhaus P, Bechstein WO, Roissant R, Riess H</AU>
<TI>Evidence that intraoperative prostaglandin E1 infusion reduces impaired platelet aggregation after reperfusion in orthotopic liver transplantation</TI>
<SO>Transplantation</SO>
<YR>1993</YR>
<VL>55</VL>
<NO>4</NO>
<PG>819-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ismail-1995" MODIFIED="2010-04-08 07:45:52 -0300" MODIFIED_BY="[Empty name]" NAME="Ismail 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-04-08 07:45:52 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ismail T, Ayres R, Kiff P, McMaster P, Neuberger J</AU>
<TI>Enisoprost in liver transplantation</TI>
<SO>Transplantation</SO>
<YR>1995</YR>
<VL>59</VL>
<PG>1298-301</PG>
<IDENTIFIERS MODIFIED="2010-02-16 09:06:43 -0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1996" MODIFIED="2011-08-26 07:31:43 -0300" MODIFIED_BY="[Empty name]" NAME="Klein 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-08-26 07:23:52 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chavin KD, Uber L, Baliga P, Rajagopalan P, Cofer J</AU>
<TI>The effects of prostaglandin E1 on hepatic allograft vascular inflow: A prospective randomized double-blind study</TI>
<SO>American Surgeon</SO>
<YR>1996</YR>
<VL>62</VL>
<NO>3</NO>
<PG>184-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-26 07:31:43 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klein AS, Cofer JB, Pruett TL, Thuluvath PJ, McGory R, Uber L, et al</AU>
<TI>Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>111</VL>
<PG>710-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manasia-1996" MODIFIED="2009-03-06 15:51:53 -0300" MODIFIED_BY="[Empty name]" NAME="Manasia 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-06 15:51:53 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manasia AR, Leibowitz AB, Miller CM, Silverstein JH, Schwartz M, Delgiudice R, et al</AU>
<TI>Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>1996</YR>
<VL>182</VL>
<NO>4</NO>
<PG>347-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann-1998" MODIFIED="2010-12-21 00:41:12 -0200" MODIFIED_BY="[Empty name]" NAME="Neumann 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-04-08 07:46:23 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann UP, Kaisers U, Langrehr JM, Lang M, Glanemann M, Raakow R, et al</AU>
<TI>Treatment with PGE1 in patients after liver transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1998</YR>
<VL>30</VL>
<PG>1869-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann-2000" MODIFIED="2011-08-26 07:31:55 -0300" MODIFIED_BY="[Empty name]" NAME="Neumann 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-08-26 07:24:31 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Müller AR, Lang M, et al</AU>
<TI>Reduction of reperfusion injury with Prostacyclin I<SUB>2</SUB> after liver transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>1-2</NO>
<PG>1029-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-26 07:31:55 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Muller AR, Lang M, et al</AU>
<TI>Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial</TI>
<SO>Clinical Transplantation</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>1</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-09-05 09:18:08 -0300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Briegel-1992" MODIFIED="2010-04-08 07:51:18 -0300" MODIFIED_BY="[Empty name]" NAME="Briegel 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-04-08 07:51:18 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Department of Anesthesiology, Ludwig-Maximilians-University of Munich, GermanyFAU - Briegel, J&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:51:18 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briegel J, Haller M, Zulke C, Kilger E, Pratschke E, Jauch KW, et al</AU>
<TI>Primary graft nonfunction following orthotopic liver transplantation: treatment with prostacyclin</TI>
<SO>Transplantation Proceedings</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>6</NO>
<PG>2693-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bucuvalas-2001" MODIFIED="2010-04-08 07:51:37 -0300" MODIFIED_BY="[Empty name]" NAME="Bucuvalas 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-08 07:51:37 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pediatric Liver Care Center, Children's Hospital Research Foundation, Cincinnati, Ohio 45229, USA JohnBuc@CHMCCorgFAU - Bucuvalas, J C&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:51:37 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bucuvalas JC, Ryckman FC, Krug S, Alonso MH, Balistreri WF, Kotagal U</AU>
<TI>Effect of treatment with prostaglandin E1 and N-acetylcysteine on pediatric liver transplant recipients: a single-center study</TI>
<SO>Pediatric Transplantation</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>4</NO>
<PG>274-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Valdecasas-1994" MODIFIED="2010-04-08 07:51:49 -0300" MODIFIED_BY="[Empty name]" NAME="Garcia-Valdecasas 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-08 07:51:49 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Department of Surgery, Liver Transplant Unit, Hospital Clinic of Barcelona, SpainFAU - Garcia-Valdecasas, J C&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:51:49 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Valdecasas JC, Rull R, Grande L, Fuster J, Rimola A, Lacy AM, et al</AU>
<TI>Prostaglandin and lipoperoxide levels and postoperative liver function in human liver transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1994</YR>
<VL>26</VL>
<NO>6</NO>
<PG>3633-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giostra-1997" MODIFIED="2010-04-08 07:52:06 -0300" MODIFIED_BY="[Empty name]" NAME="Giostra 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-04-08 07:52:06 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gastroenterology, Digestive Surgery and Transplantation Unit, Hopitaux universitaires de Geneve, SwitzerlandFAU - Giostra, E&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:52:06 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giostra E, Chen H, Deng H, Buhler L, Romand JA, Hadengue A, et al</AU>
<TI>Prophylactic administration of prostaglandin E1 in liver transplantation: results of a pilot trial</TI>
<SO>Transplantation Proceedings</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>5</NO>
<PG>2381-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grazi-1994" MODIFIED="2010-04-08 07:52:22 -0300" MODIFIED_BY="[Empty name]" NAME="Grazi 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-08 07:52:22 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2nd Department of Surgery, University of Bologna, Sant'Orsola Hospital, ItalyFAU - Grazi, G L&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:52:22 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grazi GL, Mazziotti A, Jovine E, Stefanini GF, Frena A, Ercolani G, et al</AU>
<TI>Prostaglandin therapy in primary liver graft nonfunction after orthotopic transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1994</YR>
<VL>26</VL>
<NO>6</NO>
<PG>3651-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greig-1989" MODIFIED="2010-04-08 07:52:33 -0300" MODIFIED_BY="[Empty name]" NAME="Greig 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-04-08 07:52:33 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Liver Transplant Programme, University of Toronto, Ontario, CanadaFAU - Greig, P D&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:52:33 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greig PD, Woolf GM, Abecassis M, Forster J, Strasberg SM, Taylor BR, et al</AU>
<TI>Prostaglandin E1 for primary nonfunction following liver transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>2</NO>
<PG>3360-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greig-1989a" MODIFIED="2010-04-08 07:52:41 -0300" MODIFIED_BY="[Empty name]" NAME="Greig 1989a" YEAR="1989">
<REFERENCE MODIFIED="2010-04-08 07:52:41 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Liver Transplant Program, University of Toronto, Ontario, CanadaFAU - Greig, P D&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:52:41 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greig PD, Woolf GM, Abecassis M, Strasberg SM, Taylor B, Superina RA, et al</AU>
<TI>Treatment of primary liver graft non-function with prostaglandin E1 results in increased graft and patient survival</TI>
<SO>Transplantation Proceedings</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>1 Pt 2</NO>
<PG>2385-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heering-1992" MODIFIED="2010-04-08 07:53:05 -0300" MODIFIED_BY="[Empty name]" NAME="Heering 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-04-08 07:53:05 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Department of Nephrology, Heinrich Heine University, Dusseldorf, FRGFAU - Heering, P&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:53:05 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heering P, Strobach H, Schror K, Grabensee B</AU>
<TI>The role of thromboxane and prostacyclin in ciclosporin-induced nephrotoxicity</TI>
<SO>Nephron</SO>
<YR>1992</YR>
<VL>61</VL>
<NO>1</NO>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hommann-2007" MODIFIED="2010-04-08 07:53:19 -0300" MODIFIED_BY="[Empty name]" NAME="Hommann 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-08 07:53:19 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20070316&lt;br&gt;IS - 0041-1345 (Print)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;RN - 0 (Platelet Aggregation Inhibitors)&lt;br&gt;RN - 745-65-3 (Alprostadil)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:53:19 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hommann M, Kammerer D, Lehmann G, Kornberg A, Kupper B, Daffner W, et al</AU>
<TI>Prevention of early loss of bone mineral density after liver transplantation by prostaglandin E1</TI>
<SO>Transplantation Proceedings</SO>
<YR>2007</YR>
<VL>39</VL>
<PG>540-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaisers-1996" MODIFIED="2011-08-26 07:34:50 -0300" MODIFIED_BY="[Empty name]" NAME="Kaisers 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-08-26 07:34:50 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaisers U, Neumann U, Kuhlen R, Sprenger M, Neuhaus P, Rossaint R</AU>
<TI>Nitroglycerin versus epoprostenol: effects on hemodynamics, oxygen delivery, and hepatic venous oxygenation after liver transplantation</TI>
<SO>Liver Transplantation and Surgery</SO>
<YR>1996</YR>
<VL>2</VL>
<PG>455-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1999" MODIFIED="2010-04-08 07:55:12 -0300" MODIFIED_BY="[Empty name]" NAME="Klein 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-04-08 07:55:12 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein M, Geoghegan J, Wangemann R, Böckler D, Schmidt K, Scheele J</AU>
<TI>Preconditioning of donor livers with prostaglandin I2 before retrieval decreases hepatocellular ischemia-reperfusion injury</TI>
<SO>Transplantation</SO>
<YR>1999</YR>
<VL>67</VL>
<PG>1128-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornberg-2004" MODIFIED="2010-04-08 07:55:27 -0300" MODIFIED_BY="[Empty name]" NAME="Kornberg 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-08 07:55:27 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Department of General and Visceral Surgery, Friedrich-Schiller-University, Jena, Germany ArnoKornberg@meduni-jenadeFAU - Kornberg, A&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:55:27 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornberg A, Schotte U, Kupper B, Hommann M, Scheele J</AU>
<TI>Impact of selective prostaglandin E1 treatment on graft perfusion and function after liver transplantation</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>56</NO>
<PG>526-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kukita-1994" MODIFIED="2010-04-08 07:55:40 -0300" MODIFIED_BY="[Empty name]" NAME="Kukita 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-08 07:55:40 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Department of Anesthesiology, Kumamoto Chuo HospitalFAU - Kukita, I&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:55:40 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kukita I, Goto T, Shibata Y, Baba T, Sakata R, Nakayama R, et al</AU>
<TI>[Protective effects of prostaglandin E1 on postoperative liver function after cardiac surgery]</TI>
<SO>Masui. Japanese Journal of Anesthesiology</SO>
<YR>1994</YR>
<VL>43</VL>
<NO>6</NO>
<PG>898-904</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merion-1997" MODIFIED="2010-04-08 07:56:11 -0300" MODIFIED_BY="[Empty name]" NAME="Merion 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-04-08 07:56:11 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Department of Surgery, University of Michigan Medical School, Ann Arbor, USAFAU - Merion, R M&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:56:11 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merion RM</AU>
<TI>Prostaglandins in liver transplantation</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>1997</YR>
<VL>433</VL>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olthoff-2001" MODIFIED="2010-04-08 07:56:32 -0300" MODIFIED_BY="[Empty name]" NAME="Olthoff 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-08 07:56:32 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olthoff KM</AU>
<TI>Can reperfusion injury of the liver be prevented? Trying to improve on a good thing</TI>
<SO>Pediatric Transplantation</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>6</NO>
<PG>390-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peltekian-1996" MODIFIED="2011-09-05 09:18:08 -0300" MODIFIED_BY="[Empty name]" NAME="Peltekian 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-09-05 09:18:08 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Toronto Hospital, Ontario, CanadaFAU - Peltekian, K M&lt;/p&gt;" NOTES_MODIFIED="2011-09-05 09:18:08 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peltekian KM, Makowka L, Williams R, Blendis LM, Levy GA</AU>
<TI>Prostaglandins in liver failure and transplantation: regeneration, immunomodulation, and cytoprotection. Prostaglandins in Liver Transplantation Research Group</TI>
<SO>Liver Transplantation and Surgery</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>3</NO>
<PG>171-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-1998" MODIFIED="2010-04-08 07:56:56 -0300" MODIFIED_BY="[Empty name]" NAME="Ray 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-04-08 07:56:56 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Department of Medicine, Women's College Hospital, University of Toronto, Ontario, CanadaFAU - Ray, J G&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:56:56 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray JG</AU>
<TI>Prostaglandin E1 analogs do not improve renal function among either transplant or nontransplant patients: no further trials required</TI>
<SO>Transplantation</SO>
<YR>1998</YR>
<VL>66</VL>
<NO>4</NO>
<PG>476-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruwart-1996" MODIFIED="2010-04-08 07:57:09 -0300" MODIFIED_BY="[Empty name]" NAME="Ruwart 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-04-08 07:57:09 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The Upjohn Company, Kalamazoo, Michigan, USAFAU - Ruwart, M J&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:57:09 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruwart MJ, Henley KS</AU>
<TI>Prostaglandins in liver disease and liver transplantation</TI>
<SO>Gastroenterology Clinics of North America</SO>
<YR>1996</YR>
<VL>25</VL>
<NO>2</NO>
<PG>397-407</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-2003" MODIFIED="2010-04-08 07:57:19 -0300" MODIFIED_BY="[Empty name]" NAME="Sato 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-04-08 07:57:19 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;First Department of Surgery, School of Medicine, Niigata University, 1-757 Asahimachi-dori, Niigata 951-8510, JapanFAU - Sato, Yoshinobu&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:57:19 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato Y, Kurosaki I, Yamamoto S, Nakatsuka H, Oya H, Shirai Y, et al</AU>
<TI>Postoperative management for donor safety in living related donor liver transplantation</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2003</YR>
<VL>50</VL>
<NO>49</NO>
<PG>196-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheiner-1995" MODIFIED="2010-04-08 07:57:24 -0300" MODIFIED_BY="[Empty name]" NAME="Sheiner 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-04-08 07:57:24 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheiner PA</AU>
<TI>Prostaglandins in liver transplantation</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>2</NO>
<PG>592-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1996" MODIFIED="2009-09-02 22:40:10 -0300" MODIFIED_BY="[Empty name]" NAME="Smith 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-09-02 22:40:10 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Times Cited: 2&lt;br&gt;Article&lt;br&gt;English&lt;br&gt;Smith, D. G&lt;br&gt;UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH POLICY &amp;amp; MANAGEMENT,109 OBSERV,ANN ARBOR,MI 48109&lt;br&gt;Cited References Count: 20&lt;br&gt;UN119&lt;br&gt;ADIS INTERNATIONAL LTD&lt;br&gt;41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND&lt;br&gt;AUCKLAND&lt;/p&gt;" NOTES_MODIFIED="2009-09-02 22:40:10 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith DG, Henley KS, Remmert CS, Hass SL, Campbell DA, McLaren ID</AU>
<TI>A cost analysis of alprostadil in liver transplantation</TI>
<SO>Pharmacoeconomics</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>6</NO>
<PG>517-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takaya-1993" MODIFIED="2011-08-26 07:36:29 -0300" MODIFIED_BY="[Empty name]" NAME="Takaya 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-08-26 07:36:29 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pittsburgh Transplant Institute, PennsylvaniaFAU - Takaya, S&lt;/p&gt;" NOTES_MODIFIED="2011-08-26 07:36:29 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takaya S, Bronsther O, Bu-Elmagd K, Ramos H, Fung JJ, Todo S, et al</AU>
<TI>Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506</TI>
<SO>Transplantation Proceedings</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>3</NO>
<PG>2381-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takaya-1995" MODIFIED="2010-04-08 07:58:00 -0300" MODIFIED_BY="[Empty name]" NAME="Takaya 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-04-08 07:58:00 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pittsburgh Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USAFAU - Takaya, S&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:58:00 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takaya S, Doyle H, Todo S, Irish W, Fung JJ, Starzl TE</AU>
<TI>Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1995</YR>
<VL>27</VL>
<NO>2</NO>
<PG>1862-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tancharoen-1992" MODIFIED="2010-04-08 07:58:08 -0300" MODIFIED_BY="[Empty name]" NAME="Tancharoen 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-04-08 07:58:08 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;National Liver Transplant Unit, Austin Hospital, Heidelberg, VictoriaFAU - Tancharoen, S&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:58:08 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tancharoen S, Jones RM, Angus PW, Michell ID, McNicol L, Hardy KJ</AU>
<TI>Prostaglandin E1 therapy in orthotopic liver transplantation recipients: indications and outcome</TI>
<SO>Transplantation Proceedings</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>5</NO>
<PG>2248-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tancharoen-1993" MODIFIED="2010-04-08 07:58:19 -0300" MODIFIED_BY="[Empty name]" NAME="Tancharoen 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-04-08 07:58:19 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Victorian Liver Transplant Unit, Austin Hospital, Heidelberg, AustraliaFAU - Tancharoen, S&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 07:58:19 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tancharoen S, Jones RM, Angus PW, Hardy KJ</AU>
<TI>Beneficial effect of prostaglandin E1 on hepatic allograft rejection following orthotopic liver transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>5</NO>
<PG>2890-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-09-05 09:24:13 -0300" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-09-05 09:24:13 -0300" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-2003" MODIFIED="2008-11-05 07:12:40 -0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Interaction revisited: the difference between two estimates</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7382</NO>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-1994" MODIFIED="2010-04-08 07:59:42 -0300" MODIFIED_BY="[Empty name]" NAME="Anonymous 1994" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Consensus conference on indications of liver transplantation</TI>
<SO>Hepatology</SO>
<YR>1994</YR>
<VL>20</VL>
<PG>63S-68S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atkins-2004" MODIFIED="2010-04-08 08:00:09 -0300" MODIFIED_BY="[Empty name]" NAME="Atkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>1490</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2010-04-08 08:00:17 -0300" MODIFIED_BY="[Empty name]" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS MODIFIED="2010-03-24 01:28:22 -0300" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15161896"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chavin-1996" MODIFIED="2011-08-26 08:10:27 -0300" MODIFIED_BY="[Empty name]" NAME="Chavin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chavin KD, Uber L, Baliga P, Rajagopalan P, Cofer J</AU>
<TI>The effects of prostaglandin E1 on hepatic allograft vascular inflow: A prospective randomized double-blind study</TI>
<SO>American Surgeon</SO>
<YR>1996</YR>
<VL>62</VL>
<NO>3</NO>
<PG>184-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2011-07-25 19:13:16 -0300" MODIFIED_BY="[Empty name]" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3616287"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2011-07-25 19:17:18 -0300" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Desch_x00ea_nes-1998" MODIFIED="2010-04-08 08:01:02 -0300" MODIFIED_BY="[Empty name]" NAME="Deschênes 1998" TYPE="JOURNAL_ARTICLE">
<AU>Deschênes M, Belle SH, Krom RA, Zetterman RK, Lake JR</AU>
<TI>Early allograft dysfunction after liver transplantation: a definition and predictors of outcome</TI>
<SO>Transplantation</SO>
<YR>1998</YR>
<VL>66</VL>
<NO>3</NO>
<PG>302-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-11-05 07:13:11 -0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ELTR-2011" MODIFIED="2011-09-05 09:22:07 -0300" MODIFIED_BY="[Empty name]" NAME="ELTR 2011" TYPE="OTHER">
<AU>European Liver Transplant Registry</AU>
<TI>Evolution of liver transplants in Europe</TI>
<SO>http://www.eltr.org</SO>
<YR>Assessed on Aug 31, 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2011" MODIFIED="2011-08-26 08:11:04 -0300" MODIFIED_BY="[Empty name]" NAME="Gluud 2011" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2011, Issue 7. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greig-1989b" MODIFIED="2011-08-26 09:00:41 -0300" MODIFIED_BY="[Empty name]" NAME="Greig 1989b" TYPE="JOURNAL_ARTICLE">
<AU>Greig PD, Woolf GM, Sinclair SB, Abecassis M, Strasberg SM, Taylor BR, et al</AU>
<TI>Treatment of primary liver graft nonfunction with prostaglandin E1</TI>
<SO>Transplantation</SO>
<YR>1989</YR>
<VL>48</VL>
<PG>447-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henley-1995a" MODIFIED="2011-08-26 08:53:07 -0300" MODIFIED_BY="[Empty name]" NAME="Henley 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Henley KS, Lucey MR, Normolle DP, Merion RM, McLaren ID, Crider BA, et al</AU>
<TI>A double-blind, randomized, placebo controlled trial of prostaglandin E1 in liver transplantation</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>366-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-11-05 07:13:41 -0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-08-26 08:12:26 -0300" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Colloboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Himmelreich-1993a" MODIFIED="2011-08-26 08:52:04 -0300" MODIFIED_BY="[Empty name]" NAME="Himmelreich 1993a" TYPE="JOURNAL_ARTICLE">
<AU>Himmelreich G, Hundt K, Bechstein WO, Rossaint R, Neuhaus P, Riess H</AU>
<TI>Influence of prostaglandin E1 infusion on hemostasis in orthotopic liver transplantation</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>1993</YR>
<VL>19</VL>
<NO>3</NO>
<PG>273-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2010-11-04 11:08:33 -0200" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-11-05 07:10:03 -0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-1996a" MODIFIED="2011-08-26 08:51:29 -0300" MODIFIED_BY="[Empty name]" NAME="Klein 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Klein AS, Cofer JB, Pruett TL, Thuluvath PJ, McGory R, Uber L, et al</AU>
<TI>Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>111</VL>
<PG>710-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-1999a" MODIFIED="2011-08-26 08:52:19 -0300" MODIFIED_BY="[Empty name]" NAME="Klein 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Klein M, Geoghegan J, Wangemann R, Böckler D, Schimidt K, Scheele J</AU>
<TI>Preconditioning of donor livers with prostaglandin I2 before retrieval disease hepatocellular ischemia-reperfusion injury</TI>
<SO>Transplantation</SO>
<YR>1999</YR>
<VL>67</VL>
<NO>8</NO>
<PG>1128-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-11-05 07:10:03 -0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neumann-1999" MODIFIED="2011-08-26 08:23:03 -0300" MODIFIED_BY="[Empty name]" NAME="Neumann 1999" TYPE="JOURNAL_ARTICLE">
<AU>Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Müller AR, Lang M, et al</AU>
<TI>Reduction of reperfusion injury with Prostacyclin I<SUB>2</SUB> after liver transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>1-2</NO>
<PG>1029-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neumann-2000a" MODIFIED="2011-08-26 08:51:46 -0300" MODIFIED_BY="[Empty name]" NAME="Neumann 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Muller AR, Lang M, et al</AU>
<TI>Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial</TI>
<SO>Clinical Transplantation</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>1</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OPTN-2010" MODIFIED="2011-09-05 09:23:39 -0300" MODIFIED_BY="[Empty name]" NAME="OPTN 2010" TYPE="OTHER">
<AU>Organ Procurement and Transplantation Network (OPTN)</AU>
<TI>Policy 3.6. Organ distribution: Allocation of livers</TI>
<SO>http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf</SO>
<YR>(accessed November 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OPTN-2011" MODIFIED="2011-09-05 09:24:13 -0300" MODIFIED_BY="[Empty name]" NAME="OPTN 2011" TYPE="OTHER">
<AU>Organ Procurement and Transplantation Network - OPTN</AU>
<TI>Deceased Donor Transplants in the U.S</TI>
<SO>http://optn.transplant.hrsa.gov</SO>
<YR>(accessed on August 26, 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pereira-2011" MODIFIED="2011-08-26 08:57:53 -0300" MODIFIED_BY="[Empty name]" NAME="Pereira 2011" TYPE="JOURNAL_ARTICLE">
<AU>Pereira TV, Ioannidis JPA</AU>
<TI>Statiscally significant meta-analyses of clinical trials have modest credibility and inflated effects</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>10</NO>
<PG>1060-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-08-26 08:24:59 -0300" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2010-04-08 08:27:24 -0300" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2011-08-26 08:25:22 -0300" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tancharoen-1992a" MODIFIED="2011-08-26 08:53:28 -0300" MODIFIED_BY="[Empty name]" NAME="Tancharoen 1992a" TYPE="JOURNAL_ARTICLE">
<AU>Tancharoen S, Jones RM, Angus PW, Michell ID, McNicol L, Hardy KJ</AU>
<TI>Prostaglandin E1 therapy in orthotopic liver transplantation recipients: indications and outcome</TI>
<SO>Transplantation Proceedings</SO>
<YR>1992</YR>
<VL>24</VL>
<PG>2248-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1999" NAME="Thompson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Sharp SJ</AU>
<TI>Explaining heterogeneity in meta-analysis: a comparison of methods</TI>
<SO>Statistics in Medicine</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>20</NO>
<PG>2693-708</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2008-11-05 07:10:03 -0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-09-05 09:25:31 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-09-05 09:25:31 -0300" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-09-01 08:33:02 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alevizacos-1993">
<CHAR_METHODS MODIFIED="2010-02-15 11:00:20 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:28:53 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Fifty eight adult orthotopic liver transplantation recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-01 08:23:22 -0300" MODIFIED_BY="[Empty name]">
<P>Intravenous prostaglandin E1 administration or not, from anaesthesia induction to 3rd post-operative day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-01 08:23:35 -0300" MODIFIED_BY="[Empty name]">
<P>Outcomes considered in this review: all-cause mortality in 24 months; primary nonfunction of the allograft (time-point not reported).</P>
<P>Other outcomes reported in the study: markers of liver injury and function; adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:33:02 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>A letter was sent to Dr. Peter Neuhaus on September 2007 to ask for additional unpublished data, but no reply was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 08:33:05 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-B_x00e4_rthel-2008">
<CHAR_METHODS MODIFIED="2010-03-24 00:00:51 -0300" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-24 00:30:41 -0300" MODIFIED_BY="[Empty name]">
<P>Forty four adult orthotopic liver transplantation recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-24 00:31:04 -0300" MODIFIED_BY="[Empty name]">
<P>Iloprost 1ng/kg/min for 7 days post-operatively.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-21 01:00:53 -0200" MODIFIED_BY="[Empty name]">
<P>Outcomes considered in this review: All-cause mortality in 30 days; primary nonfunction of the allograft within 48 hours postoperatively; liver re-transplantation (time-point not reported, probably in 30 days).</P>
<P>Other outcomes reported in the study: markers of liver injury and function; adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:33:05 -0300" MODIFIED_BY="[Empty name]">
<P>An e-mail was sent to Dr. Bärthel (erik.baerthel@med.uni-jena.de) in March 2010 to ask for additional unpublished data, but no reply was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 08:33:08 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henley-1995">
<CHAR_METHODS MODIFIED="2010-02-10 21:13:54 -0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:09:51 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>One hundred sixty adult orthotopic liver transplantation recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-01 08:32:10 -0300" MODIFIED_BY="[Empty name]">
<P>Intravenous prostaglandin E1 administration or placebo, from anhepatic phase up to the 21st post-operative day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-25 19:45:03 -0300" MODIFIED_BY="[Empty name]">
<P>Outcomes considered in this review: All-cause mortality in 180 days; primary nonfunction of the allograft (time-point not reported); liver re-transplantation in 180 days; acute kidney failure needing dialysis (during hospital stay); length of hospital stay; hypotension (within 21 days).</P>
<P>Other outcomes reported in the study: time spent in hospital within 180 days after transplantation; time spent in intensive care unit; re-operations.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:33:08 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>A letter was sent to Dr. Henley on September 2007 to ask for additional unpublished data, but no reply was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-05 09:25:31 -0300" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Hidalgo-2002">
<CHAR_METHODS MODIFIED="2011-06-13 22:18:36 -0300" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-13 22:20:08 -0300" MODIFIED_BY="[Empty name]">
<P>Ninety patients adult orthotopic liver transplantation recipients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-05 09:25:31 -0300" MODIFIED_BY="[Empty name]">
<P>Intraportal followed by intravenous administration of prostaglandin E1 in the experimental group versus no administration in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-01 08:26:27 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>Outcomes considered in this review: all-cause mortality; primary nonfunction of the allograft; liver re-transplantation; acute kidney failure needing dialysis; length of hospital stay; hypotension.</P>
<P>Other outcomes reported in the study: systemic and hepatic haemodynamics; transaminases peak; incidence of graft rejection; acute kidney injury.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-13 22:42:33 -0300" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 08:27:13 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Himmelreich-1993">
<CHAR_METHODS MODIFIED="2010-02-10 21:14:02 -0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:04:21 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Twenty adult orthotopic liver transplantation recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-01 08:27:07 -0300" MODIFIED_BY="[Empty name]">
<P>Intravenous prostaglandin E1 administration or not, from the beginning of surgery to 3rd post-operative day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-21 01:08:27 -0200" MODIFIED_BY="[Empty name]">
<P>Outcomes considered in this review: all-cause mortality and liver re-transplantation; time-point not reported for both outcomes.</P>
<P>Other outcomes reported in the study: platelet function, transfusion requirements, and coagulation tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:27:13 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We were unable to obtain Dr. Himmelreich's contact address. An e-mail was sent to Dr. RIess (co-author) on March 2009 to ask for additional unpublished data, but no reply was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 08:32:36 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ismail-1995">
<CHAR_METHODS MODIFIED="2010-02-10 21:14:07 -0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:12:52 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Eighty one adult orthotopic liver transplantation recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-01 08:32:36 -0300" MODIFIED_BY="[Empty name]">
<P>Oral or enteral enisoprost administration (a prostaglandin E1 analog) or placebo, started within 24 hours continued for three months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-21 01:27:52 -0200" MODIFIED_BY="[Empty name]">
<P>Outcomes considered in this review: All-cause mortality (time-point not reported).</P>
<P>Other outcomes reported in the study: renal function tests, acute kidney injury, graft rejection, and length of hospital stay.</P>
<P>Observation: mean length of hospital stay was reported, but standard deviation or standard error were not. Thus we were unable to include these data in the meta-analysis for this outcome.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:27:39 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>E-mail sent to Mr Tarik Ismail on September 2007, and a letter was sent to the co-author, Dr. Neuberger. Mr Tarik Ismail replied, but he was unable to provide any information.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 08:28:05 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klein-1996">
<CHAR_METHODS MODIFIED="2010-02-10 21:14:16 -0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:27:54 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>One hundred eighteen adult orthotopic liver transplant recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-01 08:27:54 -0300" MODIFIED_BY="[Empty name]">
<P>intravenous prostaglandin E1 administration or placebo (saline of 5% dextrose in water), from reperfusion to the 7th post-operative day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-01 08:27:59 -0300" MODIFIED_BY="[Empty name]">
<P>Outcomes considered in this review: all-cause mortality (24 months); primary non-function of the allograft (48 hours); acute kidney failure requiring dialysis (time-point not reported); hypotension (within 7 days).</P>
<P>Other outcomes reported in the study: profoundly deteriorating renal function, initial intensive care unit stay, markers of liver injury and function, renal function markers, coagulation tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:28:05 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>A letter was sent to Dr. Klein on September 2007, but his address had changed. We were unable to find his current address or e-mail.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 08:33:16 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manasia-1996">
<CHAR_METHODS MODIFIED="2010-02-10 21:14:31 -0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:26:36 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Twenty one adult orthotopic liver transplantation recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-15 11:26:21 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Intravenous PGE1 administration (alprostadil) or placebo (saline) started 12 hours after surgery continued for five hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-21 01:19:01 -0200" MODIFIED_BY="[Empty name]">
<P>Outcomes considered in this review: All-cause mortality within 30 days; acute kidney failure requiring dialysis (time-point not reported, probably during initial hospitalisation).</P>
<P>Other outcomes reported in the study: Postoperative renal function (glomerular filtration rate measured by single-injection clearance method with a radionuclide agent, urine output); biomarkers of hepatic function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:33:16 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>We contacted Dr. Anthony Manasia who provided unpublished data on demographics but was unable to provide details on need of re-transplantation or hospital length-of-stay.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 08:29:09 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann-1998">
<CHAR_METHODS MODIFIED="2010-02-10 21:14:39 -0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:17:36 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Thirty adult orthotopic liver transplant recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-01 08:29:05 -0300" MODIFIED_BY="[Empty name]">
<P>intravenous prostaglandin E1 administration or placebo from reperfusion to the 7th post-operative day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-21 00:50:31 -0200" MODIFIED_BY="[Empty name]">
<P>Although number of events are reported for some outcomes relevant for this review, denominators are not. Thus this trial was not included in our analyses.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:29:09 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>A letter was sent to Dr. Neumann on September 2007 to ask for additional unpublished data, but no reply was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 08:29:30 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann-2000">
<CHAR_METHODS MODIFIED="2010-02-10 21:14:49 -0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:15:59 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Thirty adult orthotopic liver transplant recipients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-25 19:50:07 -0300" MODIFIED_BY="[Empty name]">
<P>Intravenous prostacyclin (PGI<SUB>2</SUB>) administration or placebo from reperfusion to the 7th post-operative day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-01 08:29:26 -0300" MODIFIED_BY="[Empty name]">
<P>Outcomes considered in this study: all-cause mortality within 1 year; primary non-function of the allograft in 7 days; liver re-transplantation within 1 year.</P>
<P>Other outcomes reported in this study: postoperative serum aspartate aminotransferase and serum alanine aminotransferase levels, haemodynamic and O<SUB>2</SUB> transport measures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-01 08:29:30 -0300" MODIFIED_BY="Dimitrinka Nikolova">
<P>A letter was sent to Dr. Henley on September 2007 to ask for additional unpublished data, but no reply was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-07-25 19:57:34 -0300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:23:11 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Briegel-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:23:11 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:54:45 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bucuvalas-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:54:45 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:55:07 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Valdecasas-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:55:07 -0300" MODIFIED_BY="[Empty name]">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:23:22 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Giostra-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:23:22 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:54:56 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grazi-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:54:56 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:55:14 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greig-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:55:14 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:55:16 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greig-1989a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:55:16 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:57:06 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heering-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:57:06 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:23:37 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Hommann-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:23:37 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:57:02 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaisers-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:57:02 -0300" MODIFIED_BY="[Empty name]">
<P>Control group not placebo or no intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:55:31 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klein-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:55:31 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:23:43 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Kornberg-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:23:43 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:57:19 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kukita-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:57:19 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:23:50 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Merion-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:23:50 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:23:58 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Olthoff-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:23:58 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:24:04 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Peltekian-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:24:04 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:24:11 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Ray-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:24:11 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:24:13 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Ruwart-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:24:13 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:24:17 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Sato-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:24:17 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:24:20 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Sheiner-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:24:20 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:24:23 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Smith-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:24:23 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:57:28 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takaya-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:57:28 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:24:27 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Takaya-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:24:27 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-15 11:24:30 -0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Tancharoen-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-15 11:24:30 -0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-25 19:57:34 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tancharoen-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-25 19:57:34 -0300" MODIFIED_BY="[Empty name]">
<P>Patients not eligible for this systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-07-25 19:49:02 -0300" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-14 00:37:56 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alevizacos-1993">
<DESCRIPTION>
<P>No information provided. "...58 consecutive adult patients...were randomised."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 00:36:29 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-B_x00e4_rthel-2008">
<DESCRIPTION>
<P>Abstract reporting and ISRCTN Register with no details on randomisation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 19:46:37 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henley-1995">
<DESCRIPTION>
<P>Probably adequate "...patients were assigned to receive either Prostaglandin E1 or placebo infusion under a randomisation code generated by the University of Michigan School of Public Health and kept by the Division of Investigational Pharmacy, ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 22:44:55 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hidalgo-2002">
<DESCRIPTION>
<P>Probably adequate: "Randomisation was conducted with sealed envelopes. which were opened before transplant surgery"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-14 01:09:36 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Himmelreich-1993">
<DESCRIPTION>
<P>No information provided. "...prospective, randomised, and open study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 21:15:41 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ismail-1995">
<DESCRIPTION>
<P>"Subjects randomly assigned in the order of their enrolment according to a computer-generated assignment schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-14 01:36:02 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klein-1996">
<DESCRIPTION>
<P>Probably adequate. "Randomization was performed centrally by the staff of ... who distributed code sealed envelops to the pharmacies at each participating transplant center."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-17 12:56:46 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manasia-1996">
<DESCRIPTION>
<P>Adequate "Patients ... were assigned by the pharmacy, based on a table of random numbers to receive either alprostadil ... or an equivalent amount of carrier solution (normal saline)." "Physicians and research personnel did not have access to the master code that identified which patients were assigned to each group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 19:49:02 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-1998">
<DESCRIPTION>
<P>"Patients were randomised to either receive Prostaglandin E1 or placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-17 13:29:25 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-2000">
<DESCRIPTION>
<P>"Following randomisation, patients were assigned to receive either PGI<SUB>2</SUB> ... or placebo..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-14 00:34:58 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alevizacos-1993">
<DESCRIPTION>
<P>No information provided on allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 00:36:45 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-B_x00e4_rthel-2008">
<DESCRIPTION>
<P>Abstract reporting and ISRCTN Register with no details on randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 19:46:48 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henley-1995">
<DESCRIPTION>
<P>Allocation concealment done. "... patients were assigned to receive either Prostaglandin E1 or placebo infusion under a randomisation code generated by the University of Michigan School of Public Health and kept by the Division of Investigational Pharmacy, ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hidalgo-2002">
<DESCRIPTION>
<P>Use of sealed envelopes described, but it is unclear whether the envelopes were sequentially numbered and opaque: "Randomisation was conducted with sealed envelopes. which were opened before transplant surgery"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-14 01:12:41 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Himmelreich-1993">
<DESCRIPTION>
<P>No information provided. "...prospective, randomised, and open study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-14 01:21:58 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ismail-1995">
<DESCRIPTION>
<P>"None of the investigators had access to the code until the study had been completed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:28:19 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klein-1996">
<DESCRIPTION>
<P>Allocation concealment adequately done as randomisation was performed by the pharmacists: "Randomization was performed centrally by the staff of ... who distributed code sealed envelops to the pharmacies at each participating transplant center."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-17 12:54:34 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manasia-1996">
<DESCRIPTION>
<P>Adequate. See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-17 13:15:53 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-1998">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-17 13:29:52 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-2000">
<DESCRIPTION>
<P>No details provided. See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-07-25 19:48:40 -0300" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-07-25 19:46:04 -0300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alevizacos-1993">
<DESCRIPTION>
<P>Blinding was not done. "The control group received the same treatment, but without Prostaglandin E1."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-03-24 00:37:36 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-B_x00e4_rthel-2008">
<DESCRIPTION>
<P>Probably not. Abstract reporting and ISRCTN Register do not mention whether the study was blinded or not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-02-15 11:11:32 -0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Henley-1995">
<DESCRIPTION>
<P>The trial is described as double-blinded, but no details are reported on the methods used to achieve blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-06-13 22:48:34 -0300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hidalgo-2002">
<DESCRIPTION>
<P>Not blinded: "Two groups of 45 patients each were formed by randomisation. One received intra-portal prostaglandin E1 versus the control group, which received no drug at all."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-12-17 23:03:39 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Himmelreich-1993">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-07-25 19:48:07 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ismail-1995">
<DESCRIPTION>
<P>"Patients were given enisoprost 100&#956; t.d.s orally or an identical placebo..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-07-25 19:48:40 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klein-1996">
<DESCRIPTION>
<P>Blinding procedures clearly described "Control solutions consisted of vehicle (normal saline or 5 % dextrose in water) only. Individual solutions were labelled only with respect to the nature of the crystalloid vehicle, with no indication as to whether or not they contained Prostaglandin E1".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-10-17 12:56:59 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manasia-1996">
<DESCRIPTION>
<P>Probably adequate. See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-04-08 08:36:46 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-1998">
<DESCRIPTION>
<P>The trial is described as "randomised placebo-controlled", but the paper did not describe who was masked (patients, health-care staff, investigators) nor it details the placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-04-08 08:36:46 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-2000">
<DESCRIPTION>
<P>Study is described as "randomised placebo-controlled", but the paper did not describe who was masked (patients, health-care staff, investigators) nor it details the placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" NO="10">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-06-14 23:07:01 -0300" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01 CMP-001.03 CMP-001.04">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-15 11:29:23 -0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Alevizacos-1993">
<DESCRIPTION>
<P>The analyses included all randomised patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-24 00:38:24 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-B_x00e4_rthel-2008">
<DESCRIPTION>
<P>Abstract reporting and ISRCTN Register with no details on exclusions and losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-27 15:17:00 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henley-1995">
<DESCRIPTION>
<P>Patients erroneously re-randomised were excluded from analyses, but the numbers are similar, and important outcomes are reported and are also similar in both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-14 23:07:01 -0300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hidalgo-2002">
<DESCRIPTION>
<P>11 patients from 90 were excluded from analyses. "11 patients were excluded from the analysis because of technical difficulties for measuring intra-operative flows".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-15 11:28:37 -0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Himmelreich-1993">
<DESCRIPTION>
<P>All patients randomised were included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-17 23:07:00 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ismail-1995">
<DESCRIPTION>
<P>Important outcome data were available for all patients randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-15 11:26:53 -0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Klein-1996">
<DESCRIPTION>
<P>Important outcome data were available for all patients randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-15 11:25:26 -0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Manasia-1996">
<DESCRIPTION>
<P>Moderate to high risk of bias. Three patients in 24 were excluded from the analysis. One because of primary nonfunction of the graft (this could not be analysed because the assignment was not reported); one because of need of vasopressor; one because of erroneous discontinuation of the drug.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-15 11:22:55 -0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Neumann-1998">
<DESCRIPTION>
<P>Low risk of bias. One patient in 30 excluded from analysis because of a postoperative surgical complication that was not further detailed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-15 11:22:59 -0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Neumann-2000">
<DESCRIPTION>
<P>Moderate to high risk of bias. Three patients in 30 were excluded from the analysis: two because of bleeding, and one because of dislocation of hepatic catheter.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-06-13 22:51:38 -0300" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 22:46:52 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alevizacos-1993">
<DESCRIPTION>
<P>The study protocol is not available. There is insufficient information to judge this domain.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 22:53:12 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-B_x00e4_rthel-2008">
<DESCRIPTION>
<P>Only abstract available. Not possible to assess whether there was selective reporting bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 22:58:29 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henley-1995">
<DESCRIPTION>
<P>Although the protocol is not available, all the outcomes evaluated in this meta-analysis were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-13 22:51:38 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hidalgo-2002">
<DESCRIPTION>
<P>All relevant outcomes are available in the thesis report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 23:03:46 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Himmelreich-1993">
<DESCRIPTION>
<P>Protocol is not available. It is impossible to assess whether there was selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 23:07:34 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ismail-1995">
<DESCRIPTION>
<P>Protocol is not available. It is impossible to assess whether there was selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 23:15:43 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klein-1996">
<DESCRIPTION>
<P>Protocol is not available. It is impossible to assess whether there was selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 23:18:33 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manasia-1996">
<DESCRIPTION>
<P>Protocol is not available. It is impossible to assess whether there was selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 23:20:14 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-1998">
<DESCRIPTION>
<P>Protocol is not available. It is impossible to assess whether there was selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-17 23:22:48 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-2000">
<DESCRIPTION>
<P>Protocol is not available. It is impossible to assess whether there was selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:23:57 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alevizacos-1993">
<DESCRIPTION>
<P>No baseline imbalances. It is unclear whether it was stopped early or not because sample size calculation was not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:26:04 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-B_x00e4_rthel-2008">
<DESCRIPTION>
<P>Only abstract available. Baseline variables were not reported. It is unclear whether it was stopped early or not because sample size calculation was not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:26:17 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henley-1995">
<DESCRIPTION>
<P>Baseline characteristics are similar between groups. No evidence of risk for other biases. Trial was stopped when the planned sample size was reached.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hidalgo-2002">
<DESCRIPTION>
<P>Baseline characteristics are similar between groups. It is unclear whether this trial was stopped early or not because sample size calculation was not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Himmelreich-1993">
<DESCRIPTION>
<P>Baseline data according to treatment group not reported, so that large imbalances are possible. It is unclear whether this trial was stopped early or not because sample size calculation was not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:27:50 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ismail-1995">
<DESCRIPTION>
<P>Baseline characteristics are similar between groups. No evidence of risk for other biases. Trial was stopped when the planned sample size was reached.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klein-1996">
<DESCRIPTION>
<P>Baseline characteristics are similar between groups. It is unclear whether this trial was stopped early or not because sample size calculation was not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manasia-1996">
<DESCRIPTION>
<P>Baseline characteristics are similar between groups. This trial was stopped with half the planned sample size as interim analysis demonstrated lack of statistical significance on the main outcome. No formal statistical stopping rules were presented to justify the decision of stopping early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-1998">
<DESCRIPTION>
<P>Baseline data according to treatment group not reported, so that large imbalances are possible. No evidence of other sources of bias. It is unclear whether this trial was stopped early or not because sample size calculation was not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 08:33:35 -0300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumann-2000">
<DESCRIPTION>
<P>Baseline characteristics are similar between groups. It is unclear whether it was stopped early or not because sample size calculation was not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2011-02-11 11:15:19 -0200" MODIFIED_BY="Dimitrinka Nikolova" NO="7">
<NAME>Intention to treat</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2011-02-11 11:15:19 -0200" MODIFIED_BY="Dimitrinka Nikolova" NO="8">
<NAME>Early stopping</NAME>
<DESCRIPTION>
<P>Had the trial included the planned sample size or otherwise stopped based on formal stopping rules?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-09-01 08:30:50 -0300" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-09-01 08:30:50 -0300" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-06-14 23:31:19 -0300" MODIFIED_BY="Grade Profiler">Prostaglandins for adult liver transplanted patients</TITLE>
<TABLE COLS="7" ROWS="17">
<TR>
<TD COLSPAN="7">
<P>
<B>Prostaglandins for adult liver transplanted patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with adult liver transplanted patients<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> Prostaglandins<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prostaglandins</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>OR 0.84 </B>
<BR/>(0.52 to 1.37)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>610<BR/>(6 studies<SUP>3</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>151 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>130 per 1000</B>
<BR/>(85 to 196)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Primary non-function of the allograft</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>OR 0.55 </B>
<BR/>(0.23 to 1.33)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>488<BR/>(4 studies<SUP>4</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
<BR/>(15 to 83)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Liver re-transplantation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>OR 0.99 </B>
<BR/>(0.44 to 2.25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>332<BR/>(4 studies<SUP>5</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>82 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>81 per 1000</B>
<BR/>(38 to 167)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Acute renal failure requiring dialysis</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>OR 0.37 </B>
<BR/>(0.18 to 0.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>329<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>199 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>84 per 1000</B>
<BR/>(43 to 157)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Hypotension</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>OR 0.14 </B>
<BR/>(0.01 to 2.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>277<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
<BR/>(0 to 67)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (eg, the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias unclear or high in most trials.<BR/>
<SUP>2</SUP> 95% confidence interval for the odds ratio is compatible with both relevant clinical benefit or harm.<BR/>
<SUP>3</SUP> Of nine studies reporting this outcome, three were not included in the analysis due to no event.<BR/>
<SUP>4</SUP> Of six studies reporting this outcome, two were not included in the analysis due to no events.<BR/>
<SUP>5</SUP> Of five studies reporting this outcome, one was not included due to no events.<BR/>
<SUP>6</SUP> 95% confidence interval compatible with either a very large benefit or a large detrimental effect.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-07-24 21:44:50 -0300" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-07-24 21:44:50 -0300" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-07-18 15:35:27 -0300" MODIFIED_BY="[Empty name]">Characteristics of randomised trials evaluating prostaglandins for liver transplanted patients</TITLE>
<TABLE COLS="8" ROWS="11">
<TR>
<TD VALIGN="TOP">
<P>
<B>Study </B>
</P>
<P>
<B>(year of publication)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Prostaglandin scheme</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Adequate sequence generation</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Blinding</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Incomplete outcome data addressed?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Early stopping</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Alevizacos-1993" TYPE="STUDY">Alevizacos 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>58</P>
</TD>
<TD VALIGN="TOP">
<P>Prostaglandin E1, 0.1mcg/kg/h up to 0.5 mcg/kg/h.</P>
<P>From anaesthesia induction to 3rd post-operative day</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Henley-1995" TYPE="STUDY">Henley 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>160</P>
</TD>
<TD VALIGN="TOP">
<P>Prostaglandin E1, 10 a 40 mcg/h.</P>
<P>From anhepatic phase up to the 21st post-operative day.</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Adequate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hidalgo-2002" TYPE="STUDY">Hidalgo 2002</LINK>
</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>Prostaglandin E1 0.6 mcg/kg/h intra-portal followed by 100 to 200 mcg/h intravenously.</P>
<P>From reperfusion up to 4 or 5 days.</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Himmelreich-1993" TYPE="STUDY">Himmelreich 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>Prostaglandin E1, 10mcg/h up to 40mcg/h.</P>
<P>From the beginning of surgery to 3rd post-operative day.</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ismail-1995" TYPE="STUDY">Ismail 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>81</P>
</TD>
<TD VALIGN="TOP">
<P>Enisoprost, 100mcg oral ou SNG.</P>
<P>Started within 24 hours continued for 3 months.</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Adequate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Klein-1996" TYPE="STUDY">Klein 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>118</P>
</TD>
<TD VALIGN="TOP">
<P>Prostaglandin E1, 0.25mcg/kg/h up to 1mcg/kg/h.</P>
<P>From reperfusion to the 7th post-operative day.</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Manasia-1996" TYPE="STUDY">Manasia 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>Prostaglandin E1, 0.6mcg/Kg/h.</P>
<P>Started 12 hours after surgery continued for 5 hours.</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Inadequate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Neumann-1998" TYPE="STUDY">Neumann 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>Prostaglandin E1, 0.2mcg/Kg/h up to 1 mcg/kg/h.</P>
<P>From reperfusion to the 7th post- operative day.</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Neumann-2000" TYPE="STUDY">Neumann 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>Prostacyclin, 0.5mcg/kg/min up to 4 mcg/kg/min.</P>
<P>From reperfusion to the 7th post- operative day.</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-B_x00e4_rthel-2008" TYPE="STUDY">Bärthel 2008</LINK>
</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>Iloprost 1ng/kg/min for 7 days post liver transplantation</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Inadequate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NR = not reported.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-09-01 07:13:03 -0300" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-09-01 07:13:03 -0300" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Prostaglandins versus control</NAME>
<DICH_OUTCOME CHI2="3.5176371176629075" CI_END="1.366474366428401" CI_START="0.5199776974422853" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8429330902683472" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.13560148921337523" LOG_CI_START="-0.2840152834526338" LOG_EFFECT_SIZE="-0.0742068971196293" METHOD="IV" MODIFIED="2011-06-13 23:00:37 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6207207384667814" P_Q="1.0" P_Z="0.48817307015869016" Q="0.0" RANDOM="YES" SCALE="164.13" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="298" TOTAL_2="312" WEIGHT="100.0" Z="0.6932175033656567">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Prostaglandins</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prostaglandins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6015467791589573" CI_START="0.006330237384587622" EFFECT_SIZE="0.12832929782082325" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4152316394759335" LOG_CI_START="-2.1985800035871574" LOG_EFFECT_SIZE="-0.891674182055612" MODIFIED="2010-12-21 00:56:14 -0200" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.5353658977115634" STUDY_ID="STD-Alevizacos-1993" TOTAL_1="29" TOTAL_2="29" VAR="2.357348439855635" WEIGHT="2.577253286497809"/>
<DICH_DATA CI_END="8.253682444966053" CI_START="0.012291973590661828" EFFECT_SIZE="0.31851851851851853" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9166477556666752" LOG_CI_START="-1.9103783814975142" LOG_EFFECT_SIZE="-0.4968653129154196" MODIFIED="2010-03-24 00:44:15 -0300" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="1.6606091469753164" STUDY_ID="STD-B_x00e4_rthel-2008" TOTAL_1="22" TOTAL_2="22" VAR="2.7576227390180876" WEIGHT="2.2031599638613826"/>
<DICH_DATA CI_END="2.280253072472551" CI_START="0.5160275339286968" EFFECT_SIZE="1.0847457627118644" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.3579830495790023" LOG_CI_START="-0.2873271248955162" LOG_EFFECT_SIZE="0.03532796234174298" MODIFIED="2009-03-20 14:58:10 -0300" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.3790583908232134" STUDY_ID="STD-Henley-1995" TOTAL_1="77" TOTAL_2="82" VAR="0.143685263653484" WEIGHT="42.28327846264214"/>
<DICH_DATA CI_END="1.4890656750651485" CI_START="0.18194872184288183" EFFECT_SIZE="0.5205128205128206" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.1729138526812538" LOG_CI_START="-0.7400509909078263" LOG_EFFECT_SIZE="-0.28356856911328626" MODIFIED="2011-06-13 23:00:37 -0300" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.536280068373087" STUDY_ID="STD-Hidalgo-2002" TOTAL_1="37" TOTAL_2="42" VAR="0.28759631173424277" WEIGHT="21.125041477070642"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-20 14:58:21 -0300" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Himmelreich-1993" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.9850838245678073" CI_START="0.23263817207712378" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.47495653112237324" LOG_CI_START="-0.6333190232176229" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2009-03-20 14:58:32 -0300" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.6510065466717857" STUDY_ID="STD-Ismail-1995" TOTAL_1="40" TOTAL_2="41" VAR="0.42380952380952386" WEIGHT="14.33541171851761"/>
<DICH_DATA CI_END="3.923328667876115" CI_START="0.3889430853927148" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.593654691679372" LOG_CI_START="-0.41011394496808123" LOG_EFFECT_SIZE="0.09177037335564536" MODIFIED="2009-03-20 14:58:47 -0300" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.5896186659016002" STUDY_ID="STD-Klein-1996" TOTAL_1="58" TOTAL_2="60" VAR="0.34765017117958286" WEIGHT="17.47585509141042"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-20 14:58:58 -0300" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Manasia-1996" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-20 15:00:11 -0300" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-Neumann-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.96205442207326" CI_END="1.3252097385398676" CI_START="0.22539464992501218" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5465301319190099" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.1222846187120247" LOG_CI_START="-0.6470563967886732" LOG_EFFECT_SIZE="-0.2623858890383242" METHOD="IV" MODIFIED="2011-09-01 07:13:03 -0300" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.580319713979619" P_Q="1.0" P_Z="0.18125452488249988" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="250" WEIGHT="99.99999999999999" Z="1.3369023156316355">
<NAME>Primary non-function of the allograft</NAME>
<GROUP_LABEL_1>Prostaglandins</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prostaglandins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-20 22:24:13 -0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.0" STUDY_ID="STD-Alevizacos-1993" TOTAL_1="29" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5211799571700788" CI_START="0.017232117609676623" EFFECT_SIZE="0.1619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.182180594580867" LOG_CI_START="-1.7636613499641953" LOG_EFFECT_SIZE="-0.7907403776916642" MODIFIED="2010-03-24 00:45:12 -0300" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="1.1429971902987393" STUDY_ID="STD-B_x00e4_rthel-2008" TOTAL_1="22" TOTAL_2="22" VAR="1.3064425770308123" WEIGHT="15.632291726438677"/>
<DICH_DATA CI_END="2.1295457229304806" CI_START="0.1238274086917089" EFFECT_SIZE="0.5135135135135135" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3282869691353972" LOG_CI_START="-0.9071832153637295" LOG_EFFECT_SIZE="-0.28944812311416607" MODIFIED="2009-03-20 15:03:05 -0300" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.7257213020508325" STUDY_ID="STD-Henley-1995" TOTAL_1="77" TOTAL_2="82" VAR="0.5266714082503556" WEIGHT="38.77691321013951"/>
<DICH_DATA CI_END="9.334040554583396" CI_START="0.014578789490994717" EFFECT_SIZE="0.3688888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9700696834779482" LOG_CI_START="-1.8362785349485258" LOG_EFFECT_SIZE="-0.4331044257352886" MODIFIED="2011-06-13 23:02:08 -0300" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="1.6484628351514334" STUDY_ID="STD-Hidalgo-2002" TOTAL_1="37" TOTAL_2="42" VAR="2.717429718875502" WEIGHT="7.515444225154457"/>
<DICH_DATA CI_END="4.357069247199275" CI_START="0.24682779987438888" EFFECT_SIZE="1.037037037037037" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.639194462262481" LOG_CI_START="-0.6076059278960171" LOG_EFFECT_SIZE="0.015794267183231882" MODIFIED="2009-03-20 15:03:15 -0300" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.7323767209405699" STUDY_ID="STD-Klein-1996" TOTAL_1="58" TOTAL_2="60" VAR="0.5363756613756614" WEIGHT="38.07535083826735"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-20 15:03:41 -0300" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.0" STUDY_ID="STD-Neumann-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3539919543980803" CI_END="2.249745131194778" CI_START="0.43660178270842653" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9910815985171165" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3521333206067891" LOG_CI_START="-0.3599144953358767" LOG_EFFECT_SIZE="-0.0038905873645438444" METHOD="IV" MODIFIED="2011-09-01 07:12:44 -0300" MODIFIED_BY="Dimitrinka Nikolova" NO="3" P_CHI2="0.5022566187031596" P_Q="1.0" P_Z="0.9829120109234124" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="171" WEIGHT="100.0" Z="0.021418255747663158">
<NAME>Liver re-transplantation</NAME>
<GROUP_LABEL_1>Prostaglandins</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prostaglandins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5487148741001473" CI_START="0.0060143244510051565" EFFECT_SIZE="0.12380952380952381" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40632125346413733" LOG_CI_START="-2.22081314699034" LOG_EFFECT_SIZE="-0.9072459467631013" MODIFIED="2010-03-24 00:46:08 -0300" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="1.5431917513519766" STUDY_ID="STD-B_x00e4_rthel-2008" TOTAL_1="22" TOTAL_2="22" VAR="2.381440781440781" WEIGHT="7.346047545010802"/>
<DICH_DATA CI_END="2.8638341439876727" CI_START="0.40242044056334714" EFFECT_SIZE="1.0735294117647058" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.45694786264535503" LOG_CI_START="-0.39531996781691586" LOG_EFFECT_SIZE="0.030813947414219566" MODIFIED="2009-03-20 15:07:07 -0300" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.5006263424073385" STUDY_ID="STD-Henley-1995" TOTAL_1="77" TOTAL_2="82" VAR="0.2506267347121497" WEIGHT="69.80172018034749"/>
<DICH_DATA CI_END="8.544685629511026" CI_START="0.1528578704485744" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9316960890719512" LOG_CI_START="-0.8157121951165778" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2011-06-13 23:03:15 -0300" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="1.026436275942851" STUDY_ID="STD-Hidalgo-2002" TOTAL_1="37" TOTAL_2="42" VAR="1.0535714285714284" WEIGHT="16.604642771883608"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-20 15:07:14 -0300" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.0" STUDY_ID="STD-Himmelreich-1993" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="85.2030780302855" CI_START="0.12070204188872896" EFFECT_SIZE="3.206896551724138" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9304552842904308" LOG_CI_START="-0.9182853829804729" LOG_EFFECT_SIZE="0.506084950654979" MODIFIED="2009-03-20 15:07:28 -0300" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="1.6733643694486577" STUDY_ID="STD-Neumann-2000" TOTAL_1="15" TOTAL_2="15" VAR="2.800148312940304" WEIGHT="6.247589502758103"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7988955124041754" CI_END="0.7537198294990818" CI_START="0.1824865410393455" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3708688779043784" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.12279005879117252" LOG_CI_START="-0.7387691606205934" LOG_EFFECT_SIZE="-0.4307796097058829" METHOD="IV" MODIFIED="2011-09-01 07:12:28 -0300" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6151754575115076" P_Q="1.0" P_Z="0.006118404727905385" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="171" WEIGHT="100.00000000000001" Z="2.741367419090013">
<NAME>Acute kidney failure requiring dialysis</NAME>
<GROUP_LABEL_1>Prostaglandins</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prostaglandins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9961370729294521" CI_START="0.014502211815005375" EFFECT_SIZE="0.1201923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.0016808965954852038" LOG_CI_START="-1.8385657559859625" LOG_EFFECT_SIZE="-0.9201233262907239" MODIFIED="2009-03-20 15:21:51 -0300" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="1.0789952591326661" STUDY_ID="STD-Henley-1995" TOTAL_1="53" TOTAL_2="58" VAR="1.1642307692307692" WEIGHT="11.245223395517579"/>
<DICH_DATA CI_END="1.3010751230843418" CI_START="0.08044983600076974" EFFECT_SIZE="0.3235294117647059" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.1143023731173804" LOG_CI_START="-1.0944748368854404" LOG_EFFECT_SIZE="-0.49008623188403005" MODIFIED="2011-06-13 23:04:07 -0300" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.7100417166993479" STUDY_ID="STD-Hidalgo-2002" TOTAL_1="37" TOTAL_2="42" VAR="0.504159239453357" WEIGHT="25.968055446391357"/>
<DICH_DATA CI_END="1.126876278306261" CI_START="0.171802356413952" EFFECT_SIZE="0.44" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.05187623672186523" LOG_CI_START="-0.7649708837494904" LOG_EFFECT_SIZE="-0.3565473235138126" MODIFIED="2009-03-20 15:22:27 -0300" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.47982004202333267" STUDY_ID="STD-Klein-1996" TOTAL_1="58" TOTAL_2="60" VAR="0.23022727272727272" WEIGHT="56.86570026585904"/>
<DICH_DATA CI_END="20.486964579791568" CI_START="0.060261142953912814" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3114776165807254" LOG_CI_START="-1.219962635459375" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2009-03-20 15:21:38 -0300" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="1.4869805348796974" STUDY_ID="STD-Manasia-1996" TOTAL_1="10" TOTAL_2="11" VAR="2.2111111111111112" WEIGHT="5.921020892232033"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.889348779559786" CI_END="13.086331902138369" CI_START="-22.7428932320936" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.828280664977615" ESTIMABLE="YES" I2="89.8881107109207" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2011-07-25 19:25:47 -0300" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0016623888660612929" P_Q="1.0" P_Z="0.5973311733804678" Q="0.0" RANDOM="YES" SCALE="63.57" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="150.5131469799012" TOTALS="YES" TOTAL_1="90" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="0.5282423036029233">
<NAME>Length of hospital stay</NAME>
<GROUP_LABEL_1>Prostaglandins</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.669155450764263" CI_START="-24.130844549235732" EFFECT_SIZE="-14.399999999999999" ESTIMABLE="YES" MEAN_1="24.4" MEAN_2="38.8" MODIFIED="2009-03-20 15:32:10 -0300" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="22.0" SD_2="30.0" SE="4.96480783626199" STUDY_ID="STD-Henley-1995" TOTAL_1="53" TOTAL_2="58" WEIGHT="47.69552275944052"/>
<CONT_DATA CI_END="9.849512301703342" CI_START="-2.049512301703345" EFFECT_SIZE="3.8999999999999986" ESTIMABLE="YES" MEAN_1="23.97" MEAN_2="20.07" MODIFIED="2011-06-13 23:08:11 -0300" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="14.18" SD_2="12.6" SE="3.035521238467817" STUDY_ID="STD-Hidalgo-2002" TOTAL_1="37" TOTAL_2="42" WEIGHT="52.30447724055948"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.779593425870996" CI_START="0.007093271798059956" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.1404151404151404" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.4439812758411569" LOG_CI_START="-2.1491533986547706" LOG_EFFECT_SIZE="-0.8525860614068068" METHOD="IV" MODIFIED="2011-06-13 23:11:02 -0300" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.19746172838295759" Q="0.0" RANDOM="YES" SCALE="310.375291094145" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="135" TOTAL_2="142" WEIGHT="0.0" Z="1.28881696003932">
<NAME>Hypotension</NAME>
<GROUP_LABEL_1>Prostaglandins</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-20 15:41:15 -0300" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.0" STUDY_ID="STD-Henley-1995" TOTAL_1="77" TOTAL_2="82" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7795934258709964" CI_START="0.007093271798059956" EFFECT_SIZE="0.14041514041514042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.443981275841157" LOG_CI_START="-2.1491533986547706" LOG_EFFECT_SIZE="-0.8525860614068068" MODIFIED="2009-03-20 15:41:38 -0300" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="1.5232201440225666" STUDY_ID="STD-Klein-1996" TOTAL_1="58" TOTAL_2="60" VAR="2.3201996071561286" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-09-07 15:53:28 -0300" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="flow of studies new.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-09-07 15:53:28 -0300" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uy9B/iW4/+43/f72X7I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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-09-01 08:33:37 -0300" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-09-01 08:33:37 -0300" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATMAAAJGCAIAAAC4PfXmAAAdMUlEQVR42u2dsW4cuxmFF0iTYgsV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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-08-26 07:19:45 -0300" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-08-26 07:19:45 -0300" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-05 06:52:56 -0200" MODIFIED_BY="Sarah Louise Klingenberg">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-26 07:19:45 -0300" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time of search</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategies</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>April 2011.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(prostaglandin* OR prostacyclin OR alprostadil OR epoprostenol OR prostin OR enisoprost OR PGE) AND (((liver OR hepatic) AND transplant*) OR 'hepatic graft*')</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 2, 2011.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 PROSTAGLANDINS explode all trees (MeSH)<BR/>#2 (prostaglandin* or prostacyclin or alprostadil or epoprostenol or prostin or enisoprost or pge)<BR/>#3 (#1 or #2)<BR/>#4 LIVER TRANSPLANTATION explode all trees (MeSH)<BR/>#5 ((liver or hepatic) and (transplant* or graft*))<BR/>#6 (#4 or #5)<BR/>#7 (#3 and #6)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PubMed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1950 to April 2011.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 ((randomised controlled trial[pt] OR controlled clinical trial[pt] OR randomised controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR ("clinical trial"[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR ("latin square"[tw]) OR placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR comparative study[mh] OR evaluation studies[mh] OR follow-up studies[mh] OR prospective studies[mh] OR cross-over studies[mh] OR control*[tw] OR prospectiv*[tw] OR volunteer*[tw]) NOT (animal[mh] NOT human[mh]))<BR/>#2 (Search Liver Transplantation [MeSH] or Liver Transplantation or Hepatic Transplantation or Hepatic grafting)<BR/>#3 (Prostaglandins[MeSH] or Prostaglandins E, Synthetic[MeSH] or Prostaglandins E1 or Prostaglandins E2 or Prostacyclin or Alprostadil or Epoprostenol or Prostin or Enisoprost or PGE*)<BR/>#4 ((( #1) AND #2) AND #3)<BR/>#5 (#1 AND #2 AND #3)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to April 2011.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode "prostaglandin"/ all subheadings<BR/>#2 prostaglandin* or prostacyclin or alprostadil or epoprostenol or prostin or enisoprost or PGE<BR/>#3 #1 or #2<BR/>#4 explode "liver-transplantation"/ all subheadings<BR/>#5 ((liver or hepatic) and transplant*) or hepatic graft*<BR/>#6 #4 or #5<BR/>#7 #3 and #6<BR/>#8 random* or blind* or placebo* or meta-analysis<BR/>#9 #7 and #8<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Web of Science<BR/>(http://apps.isiknowledge.com)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to April 2011.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 TS=(liver transplantation) OR TS=(Hepatic transplantation) OR TS=(hepatic grafting)<BR/>#2 TS=(prostaglandins) OR TS=(prostaglandins E, synthetic) or TS=(Prostaglandisn E1) OR TS=(Prostaglandins E2)<BR/>#3 #1 AND 2<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LILACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to April 2011.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1= "Liver Transplantation" [MeSH] or Liver Transplantation or Hepatic Transplantation or Hepatic grafting<BR/>#2="Prostaglandins"[MeSH] or "Prostaglandins E, Synthetic"[MeSH] or Prostaglandins E1 or Prostaglandins E2 or Prostacyclin or Alprostadil or Epoprostenol or Prostin or Enisoprost or PGE*<BR/>#3= (randomised controlled trial[pt] OR controlled clinical trial[pt] OR randomised controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR ("clinical trial"[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR ("latin square"[tw]) OR placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR comparative study[mh] OR evaluation studies[mh] OR follow-up studies[mh] OR prospective studies[mh] OR cross-over studies[mh] OR control*[tw] OR prospectiv*[tw] OR volunteer*[tw]) NOT (animal[mh] NOT human[mh])<BR/>#4= #1 and #2 and #3<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>